STOCKPURCHASE AGREEMENT AMONG PROSPECTMEDICAL GROUP, INC., PROSPECTMEDICAL HOLDINGS, INC., UPLANDMEDICAL GROUP, A PROFESSIONAL MEDICAL CORPORATION (dba Upland Medical Group A Professional Corporation), AND JEEREDDIPRASAD, M.D. Datedas of: May 21, 2007

EX-2.3 4 a07-22221_1ex2d3.htm EX-2.3

Exhibit 2.3

STOCK PURCHASE AGREEMENT

AMONG

PROSPECT MEDICAL GROUP, INC.,

PROSPECT MEDICAL HOLDINGS, INC.,

UPLAND MEDICAL GROUP, A PROFESSIONAL MEDICAL CORPORATION
(dba Upland Medical Group A Professional Corporation),

AND

JEEREDDI PRASAD, M.D.

Dated as of: May 21, 2007

STOCK PURCHASE AGREEMENT

This Stock Purchase Agreement (the “Agreement”) is dated as of May 21, 2007 by and among Prospect Medical Group, Inc., a California professional corporation (“Group”), Prospect Medical Holdings, Inc., a Delaware corporation and an affiliate of Group (“Holdings”), Upland Medical Group, A Professional Medical Corporation, dba Upland Medical Group A Professional Corporation, a California professional corporation (“ProMed Upland”), and Jeereddi Prasad, M.D., the sole shareholder of ProMed Upland (the “ProMed Upland Shareholder”). The ProMed Upland Shareholder together with ProMed Upland are collectively referred to herein as the “ProMed Parties”.

RECITALS

A. WHEREAS, ProMed Upland is a licensed California professional corporation that operates as an independent practice association and, as such, contracts with primary care and specialty physicians (“ProMed Upland Provider Contracts”) and providers of ancillary services (“ProMed Upland Ancillary Service Contracts”) to provide professional medical services to patients (“ProMed Upland Enrollees”) through contracts with health plans (“ProMed Upland Health Plan Contracts”);

B. WHEREAS, ProMed Health Services Company, a California corporation (“ProMed Company”), through its wholly-owned subsidiary, ProMed Health Care Administrators, a California corporation (“ProMed HCA”) provides management and administrative services to independent practice associations and medical groups pursuant to long-term management agreements, and in such capacity has a management agreement with ProMed Upland (“ProMed Upland Management Agreement”);

C. WHEREAS, as a result of certain common officers, directors and/or shareholders, ProMed Upland is an affiliate of ProMed Company, ProMed HCA and Pomona Valley Medical Group, Inc., dba ProMed Health Medical Group Network of Pomona Valley Inc., a California professional corporation (“ProMed Pomona”), which also operates as an independent practice association;

D. WHEREAS, the ProMed Upland Shareholder owns of record and beneficially all of the issued and outstanding shares of common stock of ProMed Upland (the “ProMed Upland Shares”);

E. WHEREAS, Group is a licensed California professional corporation that operates as an independent practice association and, as such, contracts with physicians to provide professional medical services to patients through contracts with health plans;

F. WHEREAS, Holdings is an affiliate of Group and, through Holdings’ subsidiaries, provides management and administrative services to independent practice associations pursuant to long-term management agreements, and in such capacity has a management agreement with Group and each of Group’s subsidiaries which provides, among other things, for the issuance of Holdings’ stock in connection with certain acquisitions by Group or Group’s subsidiaries;

G. WHEREAS, upon the terms and subject to the conditions of this Agreement ProMed Upland desires to sell to Group, and Group desires to purchase from ProMed Upland, all of the ProMed Upland Shares making ProMed Upland a new subsidiary of Group (the “ProMed Upland Stock Purchase”);

H. WHEREAS, in a transaction to accompany the ProMed Upland Stock Purchase, (i) Group, through a subsidiary, is merging with ProMed Pomona with ProMed Pomona as the survivor and constituting a new subsidiary of Group (the “ProMed Pomona Acquisition”), and (ii) Holdings, through a subsidiary, is merging with ProMed Company as the survivor and constituting a new subsidiary of Holdings (the “ProMed Company Acquisition”);

I. WHEREAS, the following individuals are executive officers of ProMed Upland, ProMed Company, ProMed HCA and ProMed Pomona (i) Jeereddi Prasad, M.D., President of ProMed Company, ProMed HCA and ProMed Upland, (ii) Kishan Thapar, M.D., the Chief Executive Officer, Executive Director and Chief Medical Officer of ProMed Pomona and the Executive Director of ProMed Company and ProMed HCA and the Executive Director and Chief Medical Officer of ProMed Upland, and (iii) Bahram Barhemand, the Chief Financial Officer of ProMed Company, ProMed HCA, ProMed Pomona and ProMed Upland (each, a “ProMed Executive Officer” and collectively, the “ProMed Executive Officers”); and

J. WHEREAS, Group, Holdings and the ProMed Parties desire to make certain representations and warranties and other agreements in connection with the ProMed Upland Stock Purchase.

AGREEMENT

NOW, THEREFORE, in reliance on the foregoing recitals and in and for the consideration and representations, warranties, agreements and covenants set forth herein, the parties hereto hereby agree as follows:

ARTICLE 1.

PURCHASE AND SALE OF PROMED UPLAND SHARES

1.1 Closing; Closing Date. The consummation (the “Closing”) of the ProMed Upland Stock Purchase and the other transactions contemplated by this Agreement (collectively, the “Transaction”), shall take place at 10:00am at the offices of Theodora Oringher Miller & Richman, PC, 2029 Century Park East, 6th Floor, Los Angeles, California on June 1, 2007 in the event the conditions precedent to the performance of Group, Holdings and the ProMed Parties as set forth in Article 6 hereof are satisfied or waived on or before June 1, 2007 (the “Closing Date”).

1.2 Transfer of ProMed Upland Shares. At the Closing, the ProMed Upland Shareholders will deliver to Group one or more certificates representing all of the ProMed Upland Shares, as set forth in Schedule 1.2. Such stock certificates will be duly endorsed in blank for transfer or shall be presented with stock powers duly endorsed in blank, with such other documents as may be reasonably required by Group to effect a valid transfer of such

ProMed Upland Shares by the ProMed Upland Shareholder, free and clear of any claims, demands, liens, mortgages, encumbrances, pledges, security interests, and restrictions of any kind (collectively, “Liens”).

1.3 Purchase Price and Payment. In consideration of the sale by the ProMed Upland Shareholder to Group of the ProMed Upland Shares, Group shall pay, or shall cause Holdings to pay, the ProMed Shareholder the aggregate purchase price of Four Million Seven Hundred Thirty Nine Thousand Seven Hundred Thirty ($4,739,730) (the “Purchase Price”) as follows at Closing:

(a) An amount of cash equal to Three Million Nine Hundred Thirty-Three Thousand Nine Hundred Seventy Six and 00/100 Dollars ($3,933,976.00), or if Holdings makes the election set forth in (c) below, such greater amount of cash, in immediately available funds (the “Cash Consideration”); and

(b) The balance of the Purchase Price shall be paid in shares of the common stock of Holdings, par value $0.01 per share (“Holdings Common Stock”) with the total number of shares determined by dividing (i) the dollar amount of the balance of the Purchase Price being paid in Holdings Common Stock by (ii) the average of the closing sales prices of Holdings Common Stock as reported by the American Stock Exchange for the thirty (30) consecutive trading days preceding the day on which Holdings makes a public announcement concerning the execution of this Agreement rounded down to the nearest whole number (the “Stock Consideration”). Certificates for fractions of shares of Holdings Common Stock will not be issued. In lieu of a fraction of a share of Holdings Common Stock, the ProMed Upland Shareholder shall be entitled to receive an amount of cash equal to the fraction of a share of the Holdings Common Stock to which such ProMed Upland Shareholder would otherwise be entitled, multiplied by the average 30 day closing sale price referenced above for Holdings’ Common Stock.

(c) Notwithstanding anything to the contrary herein, while the Purchase Price will remain the aggregate amount set forth in Section 1.3 herein, Group and Holdings have the option at any time prior to the Closing Date, to reduce the amount of the Stock Consideration and increase the amount of the Cash Consideration by a like amount resulting in the ProMed Upland Shareholder receiving more cash and less Holdings Common Stock. Group’s and Holdings’ option to alter the Stock Consideration and Cash Consideration by a like amount is limited to reductions in Stock Consideration and increases in Cash Consideration and thus Group’s and Holdings’ option under this Section 1.3(c) does not permit Group or Holdings to reduce the Cash Consideration below the amount set forth in Section 1.3(a) above.

Example: Currently under (a) and (b) above, Group and Holdings are paying 83% of the Purchase Price in cash and 17%, constituting the balance, in Holdings Common Stock. Assuming for purpose of this example that Group and Holdings choose to decrease the Stock Consideration from the current 17% to 15% of the total Purchase Price, the Stock Consideration would be reduced from the current balance of $805,754 to $710,960 (15% of $4,739,730) and the Cash Consideration would increase from $3,933,976 to $4,028,770 (85% of $4,739,730).

1.4 Purchase Price Allocation. The parties agree that they shall mutually cooperate in completing the allocation of the Purchase Price as shown in Schedule 1.4 prior to the Closing Date, and agree that they shall use such allocation for purposes of federal and state tax reporting. The parties further agree to mutually cooperate in the filing of Form 8594 with the Internal Revenue Service.

1.5 Piggy-Back Registration Rights. All Holdings common stock issued as part of the Purchase Price shall be entitled to those “piggy-back registration rights” set forth on Exhibit B hereof subject to the ProMed Upland Shareholder’s execution of the Investment Representation Certificate described in Section 5.7 hereof wherein, among other things, the ProMed Upland Shareholder agrees to be subject to the terms and conditions of such piggy-back registration rights set forth in Exhibit B.

1.6 Fair Market Value. The parties agree that the Purchase Price reflects the fair market value of the ProMed Upland Shares.

ARTICLE 2.

REPRESENTATIONS AND WARRANTIES OF PROMED UPLAND AND
THE PROMED UPLAND SHAREHOLDER

In order to induce Group and Holdings to enter into this Agreement and to consummate the Transaction, ProMed Upland and the ProMed Upland Shareholder make the representations and warranties set forth in this Article 2.

2.1 Organization; Subsidiaries. ProMed Upland is a professional corporation duly organized, validly existing and in good standing in the State of California. ProMed Upland has all requisite corporate power and authority to own, lease, and operate its assets and to carry on its business as now being conducted. ProMed Upland has no partially-owned or wholly-owned subsidiaries other than the limited partnership interest in ProMed Properties, LP, a California limited partnership set forth in Section 4.9 hereof (“ProMed LP”).

2.2 Minute Book and Stock Records. The minute books and stock records of ProMed Upland are complete and accurate in all material respects and all signatures included therein are the genuine signatures of the persons indicated as signing. True, correct and complete copies of such minute books and stock records (which include a complete and accurate copy of the Articles of Incorporation and Bylaws and all amendments to both) of ProMed Upland has previously been delivered to Group. ProMed Upland is not in default under or in violation of any provision of its Articles of Incorporation or its Bylaws.

2.3 Authorization. ProMed Upland has the power and authority to enter into this Agreement and to consummate the Transaction. All actions on the part of ProMed Upland necessary for the authorization, execution, delivery and performance of this Agreement and the consummation of the Transaction, including all necessary approvals by the ProMed Upland Shareholder, have been or will be taken prior to the Closing Date, and this Agreement (including exhibits, schedules and the ancillary agreements) constitutes the legal, valid and binding obligation of ProMed Upland and the ProMed Upland Shareholder enforceable against them in accordance with its terms, except as enforceability may be restricted, limited or delayed by

applicable bankruptcy, insolvency, fraudulent conveyance, or other laws affecting creditor’s rights generally, and except as enforceability is subject to general principles of equity.

2.4 No Consent Required. Except as set forth on Schedule 2.4, neither the execution and delivery of this Agreement by ProMed Upland or the ProMed Upland Shareholder, nor the performance by them of their obligations under this Agreement, requires the consent, approval, order or authorization of, or registration, declaration or filing with any governmental entity or any third party that will not have been obtained and delivered to Group prior to the Closing Date.

2.5 No Violation of Other Agreements; No Conflicts.

(a) Neither the execution and delivery of this Agreement nor the consummation or performance of the Transaction violates, conflicts with or results in a breach of, or shall violate, conflict with or result in a breach of any lease, contract, document or agreement to which any of the ProMed Parties is a party or by which any of the ProMed Parties may be bound.

(b) Neither the execution and delivery of this Agreement nor the consummation or performance of the Transaction, will, directly or indirectly (with or without the giving of notice, or lapse of time, or both):

(i) contravene, conflict with, or result in a violation of any provision of the organizational documents of ProMed Upland;

(ii) contravene, conflict with, or result in a violation of any order, judgment or decree to which any of the ProMed Parties may be subject; or

(iii) contravene, conflict with or result in a violation of any of the terms or requirements, or give any governmental body the right to revoke, withdraw, suspend, cancel, terminate or modify, any governmental authorization that is held by any of the ProMed Parties.

2.6 Capital Structure. The authorized capital stock of ProMed Upland consists of 1,000 shares of common stock, no par value, of which 100 shares are issued and outstanding. All of the shares of ProMed Upland have been validly issued, are fully paid and non-assessable, and all are owned by the ProMed Upland Shareholder. There are no options, warrants, rights, shareholder agreements or other instruments or agreements outstanding giving any person the right to acquire any shares of capital stock of ProMed Upland, nor are there any commitments to issue or execute any such options, warrants, rights, shareholder agreements or other instruments or agreements. There are no outstanding stock appreciation rights or similar rights outstanding with respect to any of the capital stock of ProMed Upland nor are there any instruments, or agreements giving anyone the right to acquire any such rights.

2.7 Year End and Certain Interim Financial Statements. ProMed Upland has provided Group with (i) the balance sheets and income statements of ProMed Upland, for the fiscal year ended December 31, 2006 as such has been audited (the “2006 Year End Financial Statements”) and (ii) the unaudited interim balance sheets and income statements of ProMed Upland for the monthly periods subsequent to December 31, 2006 and ending March 31, 2007 (the “March Interim Financial Statements”, which together with all monthly Interim Financial

Statements prior to March 1, 2007, the “Interim Financial Statements”). The 2006 Year End Financial Statements and the Interim Financial Statements fairly present in all material respects the financial condition and results of operation of ProMed Upland as of the date and for the periods set forth therein and the 2006 Year End Financial Statements and the Interim Financial Statements, have been prepared in accordance with GAAP, applied on a consistent basis throughout the periods covered thereby, except in the case of the 2006 Year End Financial Statements, as may be indicated in the notes thereto and except that the Interim Financial Statements do not contain notes and, as unaudited statements, are subject to normal recurring audit adjustments consistent with past practice. Since the date of the February Interim Financial Statements there has not been any material adverse change to the financial condition of ProMed Upland, including no material difference in the assets and liabilities of ProMed Upland as shown on the February Interim Financial Statements.

2.8 No Undisclosed Liabilities. Except as set forth in Schedule 2.8, ProMed Upland has no liabilities or obligations of any nature (whether absolute, accrued, contingent, or otherwise) except: (i) for those shown on the 2006 Year End Financial Statements and the March Interim Financial Statements; and (ii) those incurred subsequent to March 31, 2007 in the ordinary course of business conducted in a manner consistent with past practices and custom. In the case of the IBNR (incurred but not reported) claim reserve shown on the March Interim Financial Statement or, to the extent a Subsequent Monthly Financial Statement has been delivered prior to the Closing Date as contemplated by Section 4.3, the amount shown on the latest Subsequent Monthly Financial Statement, reflects an amount of IBNR sufficient to cover all claims for dates of service prior to the Closing Date.

2.9 Tax Matters. ProMed Upland is an “S” corporation and has always been an “S” corporation. ProMed Upland has timely filed all income and franchise tax returns required to be filed by it and has timely paid in full all Taxes (defined below) owed by it for the periods ending on December 31, 2006 and has properly accrued, in accordance with GAAP, on the March Interim Financial Statements all Taxes for all periods ending on March 31, 2007. Except as provided in Schedule 2.9, all tax returns filed by or on behalf of ProMed Upland are true, accurate and complete in all material respects. Except as set forth in Schedule 2.9, (i) no action or proceeding for the assessment or collection of any Taxes is pending against ProMed Upland, (ii) no deficiency, assessment or other formal claim for any Taxes has been asserted or made against ProMed Upland that has not been fully paid or finally settled; and (iii) no issue has been formally raised by any taxing authority in connection with an audit or examination of any return of Taxes. Except as set forth in Schedule 2.9, no federal or state income tax returns of ProMed Upland have been audited or examined, and there are no outstanding agreements or waivers extending the applicable statutory periods of limitation for such Taxes for any period. All Taxes that ProMed Upland has been required to collect or withhold have been duly withheld or collected and, to the extent required, have been paid to the proper taxing authority. ProMed Upland does not have or will not have in the future any liability, fixed or contingent, for any unpaid taxes which could result in any form of transferee liability against Group. “Taxes” means taxes, charges, fees, levies, or assessments including, without limitation, income, excise, property, withholding, payroll, sales and franchise taxes, imposed by federal, state, county, local or foreign government or subdivision or agency thereof, and including any interest, penalties or additions.

2.10 Title to ProMed Pomona Shares. The ProMed Upland Shareholder is, and at the Closing Date will be, the owner, beneficially and of record, of one hundred percent (100%) of the ProMed Upland Shares, free and clear of all Liens.

2.11 Real Property.

(a) Except for the indirect interest in the building located at 4150 E. Concours Street, Ontario, CA 91764 (“Ontario Building”) solely as a result of ProMed Upland’s limited partnership interest in ProMed LP which owns five percent (5%) of the Ontario Building, ProMed Upland does not own any real property, nor has it ever owned any real property.

(b) ProMed Upland does not lease, sublease or otherwise have a right to use or to occupy any real property.

2.12 Tangible Personal Property.

(a) ProMed Upland has good, marketable and valid title to all tangible personal property owned by it free and clear of all Liens.

(b) Each item of furniture, equipment and other tangible personal property with an original cost of $1,000 or more that is owned by ProMed Upland and used in the conduct of its business is listed in Schedule 2.12(b) (the “Aggregate Tangible Personal Property”).

(c) All items constituting the Aggregate Tangible Personal Property will be retained by ProMed Upland until the Closing and considered part of the Transaction subject to the disposition in the ordinary course of business consistent with past practice (the “Tangible Personal Property”). None of the Tangible Personal Property shall be sold nor encumbered by a Lien except as specifically contemplated by this Agreement. All of the Tangible Personal Property is in good operating condition, subject to reasonable wear and tear. Except for the representation set forth above, the Tangible Personal Property is sold “AS IS-WHERE IS” with no warranty or representation of any kind as to its physical condition.

2.13 Intellectual Property. Schedule 2.13 lists all intellectual property owned by ProMed Upland. ProMed Upland owns its trade name, as set forth on Schedule 2.13. ProMed Upland does not pay, nor does it know of any reason it is obligated to pay, any royalties, license fees or other amounts to any person or entity as a result of the use of the trade names set forth on Schedule 2.13. ProMed Upland has applied for and received a fictitious name permit from the California Medical Board to use the trade name of ProMed Upland and any other trade name set forth on Schedule 2.13, which permits are currently outstanding and active (i.e., not delinquent) and will remain outstanding and active as of the Closing Date. To the knowledge of ProMed Upland, its use of such trade names does not infringe on the rights of any third party.

2.14 Contracts. Schedule 2.14 sets forth a list of all contracts, arrangements, and commitments (whether oral or written) to which ProMed Upland is a party, or by which it is bound, which are material to the business or operations of ProMed Upland (the “Material Contracts”). Material Contracts shall consist of any contract, arrangement or commitment (i) with insurance companies, managed care plans, hospitals, employers or other third parties to which health care services are provided to patients, or (ii) not entered into in the ordinary course

of business, or (iii) which involves an expenditure or receipt of funds greater than $10,000 per year; or (iv) which is not terminable without penalty and cause on 30 days or less notice, or (v) with physicians or other providers of medical services on behalf of ProMed Upland, or (vi) between ProMed Upland and any physician or person known to ProMed Upland to be an affiliate of any physician, regardless of the amount of payments called for, required or made thereunder, or (vii) between ProMed Upland and any shareholder, executive officer or director of ProMed Upland or an affiliate of such shareholder, executive officer or director (including any contracts with Chaparral Medical Group, Inc. dba Chaparral Clinics owned by Jeereddi Prasad, M.D.), or (viii) which is an employment agreement, or (ix) any other contract or agreement whether written or oral to which ProMed Upland is a party or to which it is bound as to which the breach, nonperformance, cancellation or failure to renew by any party thereto would have a material adverse effect on the business, assets, condition (financial or otherwise) or results of operations of ProMed Upland. Material Contracts shall specifically include the ProMed Upland Management Agreement, the ProMed Upland Provider Contracts, the ProMed Upland Health Plan Contracts, and the ProMed Upland Ancillary Service Contracts. ProMed Upland has, prior to the Closing, delivered to Group a correct and complete copy of each Contract. Each of the Material Contracts is a legal, valid, binding, enforceable agreement of ProMed Upland, in full force and effect, except as enforceability may be restricted, limited or delayed by applicable bankruptcy, insolvency, fraudulent conveyance, or other laws affecting creditor’s rights generally, and except as enforceability is subject to general principles of equity. Except as set forth on Schedule 2.14, there is not now and, to the knowledge of ProMed Upland, there has not been claimed or alleged by any person or entity, that a default exists, or an event that with notice or lapse of time or both would constitute a default or event of default, on the part of ProMed Upland, or to the knowledge of ProMed Upland, any other party thereto. Except as set forth on Schedule 2.14, no consent from, or notice to any third person or governmental entity is required in order to maintain in full force and effect any of the Material Contracts, other than consents that have been obtained and are unconditional and in full force and effect, except as enforceability may be restricted, limited or delayed by applicable bankruptcy, insolvency, fraudulent conveyance, or other laws affecting creditor’s rights generally, and except as enforceability is subject to general principles of equity, or consents that will be obtained which will be unconditional and in full force and effect, except as enforceability may be restricted, limited or delayed by applicable bankruptcy, insolvency, fraudulent conveyance, or other laws affecting creditor’s rights generally, and except as enforceability is subject to general principles of equity, and such notices that have been given and copies of such consents have been delivered to Group.

All Material Contracts which constitute “affiliate agreements” are noted as such on Schedule 2.14.

2.15 Legal Proceedings. Except as set forth on Schedule 2.15(a) (“Existing/Threatened Claims”), there is no pending claim, suit, action, investigation, legal or administrative proceeding (“Proceeding”), and, to the knowledge of ProMed Upland, no person, entity or authority (including, but not limited to, any employee, agent, contractor or provider of ProMed Upland) has threatened to commence any Proceeding or any investigation that could lead to a Proceeding: (i) against ProMed Upland (including, without limitation, any workers’ compensation, Equal

Employment Opportunity Commission or Americans With Disability Act claims) or that otherwise relates to or may affect the business of ProMed Upland or any of the other assets owned or used by ProMed Upland; or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal, or otherwise interfering with, any part of the Transaction. To the knowledge of ProMed Upland, no person, entity or authority (including, but not limited to, any employee, agent, contractor or provider of ProMed Upland) has threatened to commence any Proceeding or any investigation that could lead to a Proceeding against any employee, agent, contractor or provider of any of the ProMed Parties for conduct which would give rise to a potential indemnification obligation of ProMed Upland. There is no outstanding order, judgment, writ, injunction or decree of any court or any federal, state, local or other governmental department, commission, board, bureau, agency or instrumentality, to which ProMed Upland or any of the other assets owned or used by ProMed Upland, is subject that has not been fully complied with to the satisfaction of such governmental entity. Except as set forth on Schedule 2.15(b), to the knowledge of ProMed Upland, the costs of defense, and any amount that may be owing upon any judgment or settlement of the Existing/Threatened Claims are covered by one or more of the insurance policies described in Section 2.18, subject only to the customary deductibles set forth in such insurance policies.

2.16 Compliance with Laws. ProMed Upland is not in violation of any law, rule, regulation or administrative or judicial order pertaining to the assets or the business of ProMed Upland (including, without limitation, licensing, health care, federal, state or local laws relating to kickbacks, illegal referrals, illegal billings or the like, drug enforcement, securities, zoning, building, environmental, immigration, civil rights and occupational health and safety laws, regulations, ordinances and codes) which would have a material adverse effect on the assets or the business of ProMed Upland or would have the effect of delaying, making illegal or otherwise interfering with, any part of the Transaction. To the best of its knowledge, ProMed Upland has no reason to anticipate that existing circumstances are likely to result in violations of any of the foregoing.

2.17 Employees. Set forth on Schedule 2.17 are the following:

(a) A complete and accurate list of the names, titles, dates of hire and rates of pay of all employees of ProMed Upland as of the date hereof. Except as set forth separately on Schedule 2.17, (i) all employees are “at will” employees, and no written or oral employment, consultant or independent contractor agreement exists with respect to ProMed Upland to which ProMed Upland may be bound, (ii) no employees are members of a labor union in connection with their employment with ProMed Upland or subject to a collective bargaining agreement with ProMed Upland, and (iii) to the knowledge of ProMed Upland, no employees are subject to or party to any contract or agreement restricting their ability to freely engage or compete in any business.

(b) A description of each employee benefit or compensation plan, including without limitation, pension, retirement, deferred compensation, profit sharing, bonus or incentive, medical, dental, health insurance and life insurance or other employee benefit plans, arrangements or undertakings of ProMed Upland applicable to its employees.

(c) A complete and accurate list of all holiday and vacation pay accrued as of March 31, 2007 for all employees of ProMed Upland.

Except as set forth in Schedule 2.17, ProMed Upland is not a party to, bound by, nor does it maintain or make any contribution to, nor has it incurred any expense with respect to any employment agreement, pension, retirement, deferred compensation, profit sharing, bonus or incentive plan, medical, dental or other health insurance plan, life insurance plan, or other employee benefit plan, program, arrangement or undertaking, whether or not legally binding (including, without limitation, any “employee benefit plan” as defined in Section 3(3) of the federal Employee Retirement Income Security Act (“ERISA”)), under which employees of ProMed Upland are eligible to participate or derive a benefit (collectively “Employee Plans” and individually “Employee Plan”).

(d) As of the Closing, there will be no liability of ProMed Upland which has not been properly accrued on the ProMed Financial Statements for any Employee Plan or unpaid compensation, tax withholdings, wrongful termination, Federal Insurance Contribution Act and disability payments of any kind with respect to any employee or independent contractor providing services to ProMed Upland, including without limitation, vacation pay, sick leave pay, personal day pay, severance pay and bonus pay.

2.18 Insurance. Schedule 2.18 contains a list of all insurance policies maintained by or for the benefit of ProMed Upland through the Closing Date, including errors and omission, stop-loss (reinsurance), directors and officers, general liability, worker’s compensation and malpractice insurance policies (the “Insurance Policies”). The Insurance Policies are in full force and effect as of the date hereof in accordance with their respective terms, and such Insurance Policies will continue in full force and effect through the Closing Date.

2.19 Management; Powers of Attorney. Schedule 2.19 sets forth all current appointed and acting officers and directors of ProMed Upland (or other applicable managers or governing board members) and lists all general and special powers of attorney granted by ProMed Upland, including the names of the attorneys-in-fact appointed under those powers of attorney and the respective dates in which those powers were granted.

2.20 No Bankruptcy Proceedings. ProMed Upland has not (i) made a general assignment for the benefit of creditors, (ii) filed any voluntary petition in bankruptcy or suffered the filing of an involuntary petition by its creditors, (iii) suffered the appointment of a receiver to take possession of all or substantially all of its assets, property or business, (iv) suffered the attachment or other judicial seizure of all or substantially all of its assets, property or business, (v) admitted in writing its inability to pay its debts as they come due, or (vi) made an offer of settlement, extension or compromise to its creditors generally.

2.21 Licensure. As of the date hereof, each of the employees of ProMed Upland who is required to be licensed in connection with the delivery of health care services is duly licensed without restriction.

2.22 Environmental. ProMed Upland has complied with all federal, state and local environmental laws, rules and regulations as in effect on the date hereof applicable to its business

and its assets. To the knowledge of ProMed Upland, no hazardous or toxic waste, substance, material or pollutant (as those or similar terms are defined under the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended, 42 U.S.C. 9601 et seq., Toxic Substances Control Act, 15 U.S.C. 2601 et seq., the Resource Conservation and Recovery Act of 1976, 42 U.S.C. 6901 et seq. or any other applicable federal, state and local environmental law, statute, ordinance, order, judgment, rule or regulation relating to the environment or the protection of human health (“Environmental Laws”)), including but not limited to, any asbestos or asbestos related products, oils or petroleum-derived compounds, CFCs or PCBs, have been released, emitted or discharged or are currently located in, on, under, or about the real property on which the assets or the business of ProMed Upland are located. The assets of ProMed Upland and its use thereof, and ProMed Upland’s operation of its business, is not in violation of any Environmental Laws nor any occupational, safety and health law now in effect.

2.23 Confidentiality and Non-Compete Arrangements. Except as set forth on Schedule 2.23, ProMed Upland is not a party to or is bound or affected by, any confidentiality or non-compete agreements or arrangements, or any acquisition or sale or other agreements that contain any confidentiality or non-compete agreements or arrangements, that are currently in effect, or are contained in agreements or arrangements that have lapsed but which contain continuing confidentiality or non-compete obligations, agreements or arrangements.

2.24 Inspections. Schedule 2.24 sets forth accurately and fully describes (i) all inspections of ProMed Upland conducted by any governmental agency or health plan at any time during the five (5) year period preceding the date of this Agreement, which inspection detected matters requiring correction or modification, and where such violation has not been resolved to the satisfaction of such inspecting party. ProMed Upland has delivered a copy of all inspection reports referred to in this Section 2.24 which reflect all matters which were noted by any and all such governmental agencies or health plans as requiring correction or modifications which were requested or recommended.

2.25 Reimbursement Status. As of the date hereof:

(a) To the extent that ProMed Upland is participating in the Medicare and Medicaid programs or in other applicable governmental health care payment programs, and is authorized to receive reimbursement from such programs for fees and charges incurred by eligible patients for services of such programs, ProMed Upland knows of no reason why Group Subsidiary will not be able to continue to participate in such governmental health care payment programs to the same extent, if any, that ProMed Upland participates. ProMed Upland has not received any notice that any such license, participation or authorization has been or is threatened to be terminated or restricted, and ProMed Upland does not know of any basis for any such termination or restriction. To the knowledge of ProMed Upland, there is no federal or state investigation pending or contemplated, that will have an impact upon the reimbursement status of ProMed Upland or ProMed Upland’s ability to operate its business as currently conducted. ProMed Upland has not received any notice of action nor, to the knowledge of ProMed Upland, is there any threatened or likely action by the Medicare or Medicaid program or any carrier, to recoup or challenge any Medicare or Medicaid reimbursement that ProMed Upland has received

or for which ProMed Upland currently has a claim pending for services rendered in connection with its business.

(b) All billing practices by ProMed Upland or ProMed HCA on behalf of ProMed Upland, to all third parties including, but not limited to, Medicare, Medicaid and private insurance companies, have been true, fair and correct and in compliance with all applicable laws, regulations and policies of all such third party payors, and neither ProMed Upland nor ProMed HCA on behalf of ProMed Upland has billed for or received any payment or reimbursement in excess of amounts permitted by law.

2.26 Absence of Certain Business Practices. Neither ProMed Upland nor to the knowledge of ProMed Upland, ProMed HCA on behalf of ProMed Upland, or any of their respective agents, directly or indirectly (i) offered to pay or solicited any remuneration, in cash or in kind, to, or made any financial arrangements with, any past or present customers, past or present suppliers, contractors, third parties, or third party payors of ProMed Upland in order to obtain business or payments from such persons; other than entertainment activities in the ordinary and lawful course of business; (ii) given or received, or agreed to give or receive, or is aware that there has been made or that there is any agreement to make or receive, any gift or gratuitous payment of any kind, nature or description (whether in money, property or services) to any customer or potential customer, supplier or potential supplier, contractor, third party payor or any other person other than in connection with promotional or entertainment activities in the ordinary and lawful course of business; (iii) made or agreed to make, or is aware that there has been made or that there is any agreement to make any contribution, payment or gift of funds or property to, or for the private use of, any governmental official, employee or agent where either the contribution, payment or gift or the purpose of such contribution, payment or gift is or was illegal under the laws of the United States or under the laws of any state thereof or any other jurisdiction under which such payment, contribution or gift was made; (iv) established or maintained any unrecorded fund or asset for any purpose or made any false or artificial entries on any of its books or records for any reason; or (v) made or agreed to make or is aware that there has been made or that there is any intention to make, any payment to any person with the intention or understanding that any part of such payment would be used for any purpose other than that described in the documents supporting such payment.

2.27 Permits. Schedule 2.27 sets forth a list of all permits, licenses and approvals from federal, state, local and foreign governmental and regulatory bodies (collectively “Permits”) held by ProMed Upland and relating to the assets which are a part of the Transaction. Such Permits constitute all of the Permits necessary to conduct the business of ProMed Upland, as applicable, in the manner now conducted by ProMed Upland. No breach of any such Permit currently exists, nor has any event occurred which through the passage of time or the giving of notice or both, would constitute a breach thereunder. To the knowledge of ProMed Upland, none of the Permits is to be or proposed to be suspended, canceled or revoked or amended, modified or limited in any fashion.

2.28 Fraud and Abuse. Except as set forth in Schedule 2.28, neither ProMed Upland, nor any individual or entity having an ownership interest in, or who is an officer, director or licensed healthcare employee of ProMed Upland has been convicted of, or investigated for, a Medicare or Medicaid health program related offense. To the knowledge of ProMed Upland, no

individual or entity having an ownership interest in, or who is an officer, director or licensed healthcare employee of ProMed Upland has been convicted or charged with any federal or state health program related offense or convicted of, charged with or investigated for a violation of federal or state law related to fraud, theft, embezzlement, breach of fiduciary responsibility, financial misconduct, obstruction of an investigation or controlled substances, or has been excluded or suspended from participation in a state health program or has been subject to any order or consent decree of, or criminal or civil fine or penalty imposed by, any court or governmental agency. Except as set forth in Schedule 2.28 no claim, complaint, suit, action, or proceeding (collectively “Proceeding”) is pending nor, to the knowledge of ProMed Upland, is any Proceeding threatened or any investigation that could lead to a Proceeding occurring against ProMed Upland, or any individual or entity having an ownership interest in, or who was an officer or director of, ProMed Upland, which may result in any restraint, prohibition or the obtaining of damages or any other relief. ProMed Upland has implemented a formal compliance program designed to assure compliance with applicable fraud and abuse laws.

2.29 Recoupment. There is no action or threatened action for recoupment against ProMed Upland, nor is there any request for payments by ProMed Upland to Medicare or of reimbursement from ProMed Upland by Medicare, nor by any other agency affiliated with Medicare, nor by or from any third-party reimburser, including, without limitation, any insurance carrier, pre-paid plan, or any other similar entity, nor does ProMed Upland have knowledge of any basis for such recoupment by any party. None of the accounts of ProMed Upland has been acquired by unlawful special arrangements or kickbacks, or other unlawful acts.

2.30 Enrollment Information and Eligibility Reports. The enrollment information of ProMed Upland set forth in the March Interim Financial Statements were prepared from the eligibility reports of the health plans who are a party to the ProMed Upland Health Care Contracts. The enrollment information set forth in the March Interim Financial Statements accurately and completely describes the information provided in the eligibility reports of the health plans as to the enrollment numbers of ProMed Upland, and are true, accurate and complete in all material respects.

2.31 Disclosure. No representation or warranty by ProMed Upland contained in this Agreement or in respect of the exhibits, schedules, lists or other documents delivered to Group by ProMed Upland or the ProMed Upland Shareholder and referred to herein or therein, and no statement contained in any certificate furnished or to be furnished by or on behalf of ProMed Upland pursuant hereto or thereto, or in connection with the Transaction, contains, or will contain as of the date such representation or warranty is made or such certificate is or will be furnished, any untrue statement of a material fact, or omits, or will omit to state as of the date such representation or warranty is made or such certificate is or will be furnished, any material fact which is known to the party making the representation or warranty to be necessary to make the statements contained herein or therein, in light of the circumstances under which they were made, not misleading.

2.32 Bank Accounts. A correct and complete list of all bank accounts of ProMed Upland (“ProMed Bank Accounts”) and the persons authorized to access such accounts and to incur indebtedness on behalf of ProMed Upland, is set forth in Schedule 2.32 of this Agreement. Except as set forth on Schedule 2.32, all monies in the ProMed Bank Accounts are in cash (and

not securities of any nature) and constitute “good funds” subject to immediate withdrawal by Group.

2.33 Brokers’ and Finders’ Fees. Neither ProMed Upland nor the ProMed Upland Shareholder has incurred any liability to any broker, finder or agent for any brokerage fees, finder’s fees or commissions with respect to the transactions contemplated by this Agreement, and if ProMed Upland or the ProMed Upland Shareholder has incurred any such liability, such liability shall be and remain the sole responsibility of ProMed Upland and the ProMed Upland Shareholder, and the ProMed Parties shall indemnify, defend and hold Group harmless from and against any and all liabilities, losses, damages, claims, causes of action, costs and expenses (including without limitation, reasonable attorneys’ fees), arising out of or relating to such liability.

2.34 Primary Care Physicians at Chaparral Clinics. ProMed Upland represents that the primary care physicians at the Chaparral Clinics are exclusive to ProMed Upland and ProMed Pomona.

ARTICLE 3.

REPRESENTATIONS AND WARRANTIES OF GROUP
AND HOLDINGS

In order to induce ProMed Upland and the ProMed Upland Shareholder to enter into this Agreement and to consummate the Transaction, Group and Holdings make the representations and warranties set forth in this Article 3.

3.1 Organization. Group is a professional corporation duly organized, validly existing and in good standing under the laws of the State of California. Holdings is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. Each of Group and Holdings has all requisite authority to own, lease, and operate its assets and to carry on its business as currently being conducted.

3.2 Authorization. Each of Group and Holdings has the power and authority to enter into this Agreement and to consummate the Transaction. All actions on the part of Group and Holdings necessary for the authorization, execution, delivery and performance of this Agreement and the consummation of the Transaction have been or will be taken prior to the Closing Date, and this Agreement (including exhibits, schedules and the ancillary agreements) constitutes the legal, valid and binding obligation of Group and Holdings, as applicable, enforceable against them in accordance with its terms, except as enforceability may be restricted, limited or delayed by applicable bankruptcy, insolvency, fraudulent conveyance, or other laws affecting creditor’s rights generally, and except as enforceability is subject to general principles of equity.

3.3 No Consent Required. Except as set forth in Schedule 3.3, neither the execution and delivery of this Agreement by Group or Holdings nor the performance by them of their obligations under this Agreement requires the consent, approval, order or authorization of, or registration, declaration or filing with any governmental entity or any third party that will not have been obtained and delivered to ProMed Upland prior to the Closing Date.

3.4 No Violation of Other Agreements; No Conflicts.

(a) Neither the execution and delivery of this Agreement nor the consummation or performance of the Transaction violates, conflicts with or results in a breach of, or shall violate, conflict with or result in a breach of any lease, contract, document or agreement to which Group and/or Holdings is a party or by which Group and/or Holdings may be bound.

(b) Neither the execution and delivery of this Agreement nor the consummation or performance of the Transaction will, directly or indirectly (with or without the giving of notice, or lapse of time, or both):

(i) contravene, conflict with, or result in a violation of any provision of the organizational documents of Group and/or Holdings;

(ii) contravene, conflict with, or result in a violation of, any legal requirement or any order, judgment or decree to which Group and/or Holdings may be subject; or

(iii) contravene, conflict with, or result in a violation of any of the terms or requirements of, or give any governmental body the right to revoke, withdraw, suspend, cancel, terminate, or modify, any governmental authorization that is held by Group and/or Holdings.

Except as specifically contemplated by this Agreement and as required under the Securities Act and any applicable state securities laws, Holdings is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under or contemplated by this Agreement in accordance with the terms hereof or thereof. All consents, authorizations, orders, filings and registrations which Holdings is required to obtain pursuant to the preceding sentence have been obtained or will be obtained prior to Closing.

3.5 Capital Structure. The authorized capital stock of Holdings consists of 40,000,000 shares of Common Stock and 5,000,000 shares of preferred stock, par value $0.01 (“Preferred Stock”) of which 7,939,990 shares of Common Stock and zero shares of Preferred Stock were issued and outstanding as of May 10, 2007 as reflected in Holdings’ most recent quarterly report filed May 15, 2007 with the Securities and Exchange Commission (“SEC”). All of the outstanding shares have been validly issued and are fully paid and non-assessable. Except as disclosed in the SEC Documents (as defined in Section 3.7), no shares of Common Stock are subject to outstanding options, warrants, rights, shareholder agreements or other instruments or agreements outstanding giving any person the right to acquire any shares of capital stock of Holdings, nor are there any commitments to issue or execute any such options, warrants, rights, shareholder agreements or other instruments or agreements. There are no outstanding stock appreciation rights or similar rights outstanding with respect to any of the capital stock of Holdings nor are there any instruments, or agreements giving anyone the right to acquire any such rights.

3.6 Issuance of Securities. The Common Stock is duly authorized and, upon issuance in accordance with the terms hereof, shall be duly issued, fully paid and non-assessable, and free from all Liens.

3.7 SEC Documents; Holdings Consolidated Financial Statements. Since May 27, 2004 when Holdings became an SEC reporting company, Holdings has filed all reports, schedules, forms, statements and other documents required to be filed by it with the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (all of the foregoing filed prior to the date hereof or amended after the date hereof and all exhibits included therein and financial statements and schedules thereto and documents incorporated by reference therein, being hereinafter referred to as the “SEC Documents”). Holdings has delivered to the ProMed Parties or their representatives, or made available through the SEC’s website at http://www.sec.gov, true and complete copies of the SEC Documents. As of their respective dates, the financial statements of Holdings disclosed in the SEC Documents (the “Holdings Consolidated Financial Statements”) complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such Holdings Consolidated Financial Statements have been prepared in accordance with GAAP, applied on a consistent basis throughout the periods covered thereby (except (i) as may be otherwise indicated in such Holdings Consolidated Financial Statements or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements and, as unaudited statements, are subject to normal recurring audit adjustments consistent with past practice) and, fairly present in all material respects the financial position of Holdings as of the dates thereof and the results of its operations. The Holdings Consolidated Financial Statements do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.

3.8 Legal Proceedings. There is no pending Proceeding, and, to the knowledge of Group and/or Holdings, no person has threatened to commence any Proceeding that challenges, or that may have the effect of preventing, delaying, making illegal, or otherwise interfering with, any part of the Transaction.

3.9 Compliance with Laws. Neither of Group nor Holdings is in violation of any rule, regulation or administrative or judicial order pertaining to the assets or the business of Group and/or Holdings (including, without limitation, licensing, health care, federal, state or local laws relating to kickbacks, illegal referrals, illegal billings or the like, drug enforcement, securities, zoning, building, environmental, immigration, civil rights and occupational health and safety laws, regulations, ordinances and codes) which would have the effect of preventing, delaying, making illegal, or otherwise interfering with, any part of the Transaction. To their knowledge, none of Group nor Holdings has any reason to anticipate that existing circumstances are likely to result in violations of any of the foregoing.

3.10 Disclosure. No representation or warranty by Group and/or Holdings contained in this Agreement or in respect of the exhibits, schedules, lists or other documents delivered to the ProMed Parties by Group and/or Holdings and referred to herein or therein, and no statement contained in any certificate furnished or to be furnished by or on behalf of Group and/or Holdings pursuant hereto or thereto, or in connection with the transactions contemplated hereby,

contains, or will contain as of the date such representation or warranty is made or such certificate is or will be furnished, any untrue statement of a material fact, or omits, or will omit to state as of the date such representation or warranty is made or such certificate is or will be furnished, any material fact which is known to the party making the representation or warranty to be necessary to make the statements contained herein or therein, in light of the circumstances under which they were made, not misleading.

3.11 Brokers’ and Finders’ Fees. Neither Group nor Holdings has incurred any liability to any broker, finder or agent for any brokerage fees, finder’s fees or commissions with respect to the transactions contemplated by this Agreement, and if Group or Holdings has incurred any such liability, such liability shall be and remain the sole responsibility of Group and Holdings, and Group and Holdings shall indemnify, defend and hold the ProMed Parties harmless from and against any and all liabilities, losses, damages, claims, causes of action, costs and expenses (including without limitation, reasonable attorneys’ fees), arising out of or relating to such liability.

3.12 Financing. Holdings and Group shall use their best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable to arrange financing acceptable to Holdings and Group to fund the Cash Consideration.

ARTICLE 4.

COVENANTS OF PROMED UPLAND AND PROMED UPLAND SHAREHOLDER

In order to induce Group and Holdings to enter into this Agreement and to consummate the Transaction, ProMed Upland and the ProMed Upland Shareholder enter into the agreements set forth in this Article 4.

4.1 Conduct of Business - Negative Covenants. From the date hereof until the Closing Date, ProMed Upland shall not, without the prior written consent of Group, which consent shall not be unreasonably withheld, conduct the business of ProMed Upland other than in the ordinary course of ProMed Upland’s business as conducted through the date hereof or commit or suffer any material act or omission which deviates from the ordinary course of ProMed Upland’s business as conducted through the date hereof. Without limiting the generality of the foregoing, from the date of execution of this Agreement until the Closing Date, ProMed Upland shall not, without the prior written consent of Group, which consent shall not be unreasonably withheld:

(a) institute any new method of purchase, sale, lease, management, accounting or operation or engage in any transaction or activity, enter into any agreement or make any commitment or amend any existing material agreement other than as contemplated by this Agreement, except in the ordinary course of its business and consistent with past practice;

(b) change or amend its Articles of Incorporation or By-Laws or propose any such change or amendment;

(c) offer, issue, authorize or sell any shares of the capital stock or other securities (such term as used in this subsection shall include, without limitation, debt securities) of ProMed Upland of any kind whatsoever, or acquire directly or indirectly, by redemption

or otherwise, any such capital stock, reclassify or split-up any such capital stock, declare or pay any dividends thereon in cash, securities or other property, or make any other distribution with respect thereto, or grant or enter into any stock options, warrants, or other rights to acquire securities of ProMed Upland or enter into any other contracts or commitments of any kind with respect to the issuance of additional shares of capital stock or other securities of ProMed Upland;

(d) (i) borrow or agree to borrow any funds, whether directly or by way of guaranty or otherwise, or (ii) except in the ordinary course of business and consistent with past practice, incur, or assume or become subject to any obligation or liability (absolute or contingent);

(e) pay, discharge, waive, satisfy, compromise or adjust any claim, liability or obligation (absolute, accrued, contingent or otherwise) of an amount in excess of $10,000, other than as contemplated by this Agreement or occurring in the ordinary course of business and consistent with past practice;

(f) prepay any obligation having a fixed maturity of more than 90 days from the date such obligation was incurred other than as contemplated by this Agreement or occurring in the ordinary course of business and consistent with past practice;

(g) permit or allow any of its property or assets (real, personal or mixed, tangible or intangible) to be subjected to any mortgage, pledge, lien or other encumbrance except in the ordinary course of business and consistent with past practice;

(h) cancel any debts or waive any claims or rights of substantial value or sell, transfer, or otherwise dispose of any of its properties or assets, except in the ordinary course of its business and consistent with past practice;

(i) dispose of any rights to the use of any patent, trademark, service mark, trade name or copyright, or dispose of or disclose to any person any trade secret, formula, process or know-how not theretofore a matter of public knowledge, except in the ordinary course of its business and consistent with past practice;

(j) grant any general increase in the compensation of officers or employees (including any such increase pursuant to any bonus, pension, profit sharing or other plan or commitment) or any increase in the compensation (including salary and bonus) payable or to become payable to any officer except in the ordinary course of business and consistent with past practice;

(k) appoint or remove from office any officers of ProMed Upland other than as contemplated by this Agreement;

(l) make any payment to or sell, transfer or lease any properties or assets to, or enter into any agreement or arrangement with, any of the officers or directors of ProMed Upland or any other affiliate thereof, except in the ordinary course of its business and consistent with past practice;

(m) enter into any contract, commitment or transaction not in the usual and ordinary course of its business, other than transactions contemplated by, or referred to in, this Agreement;

(n) change, or initiate a change of, any of the banking, safe deposit or power of attorney arrangements effective as of the date hereof, except for changes in the signatories on the accounts of ProMed Upland, provided such changes are contemplated by this Agreement and ProMed Upland shall have given Group prior written notice of any such change in signatories and Group approves same;

(o) write down the value of any inventory (including write-downs by reason of shrinkage or mark-down) or write off as uncollectible any notes or accounts receivable, except for immaterial write-downs of inventory or accounts receivable in the ordinary course of business and consistent with past practice;

(p) merge, consolidate, reorganize or liquidate ProMed Upland;

(q) file a voluntary petition on behalf of ProMed Upland under the U.S. Bankruptcy Code or any other bankruptcy or insolvency law or any other law for relief of debtors;

(r) change, amend or terminate a Material Contract constituting an affiliate agreement under Section 2.14 except as contemplated by this Agreement or with the written consent of Group; or

(s) agree or commit, whether in writing or otherwise, to do any of the foregoing.

Notwithstanding the foregoing, ProMed Upland may at any time prior to the Closing Date, (i) pay the Stay Bonuses described in Section 5.2 and (ii) distribute cash to the ProMed Upland Shareholder provided such distribution shall not cause ProMed Upland to violate the covenant set forth in Section 4.4 or any other representation, warranty, covenant or agreement provided herein.

4.2 Conduct of Business - Affirmative Covenants. Prior to the Closing Date, ProMed Upland will conduct its business in the ordinary course and will:

(a) maintain its good standing and qualification to do business in all jurisdictions where it is required to be qualified to do business, and all licenses, permits, franchises, rights and privileges which are necessary for the conduct of its business;

(b) continue at its expense to maintain all of its property and equipment in customary repair, order and working condition, reasonable wear and use excepted;

(c) duly comply with all laws, regulatory requirements and agreements to which it, or any of its properties or assets, is subject or by which it is bound;

(d) maintain in force and effect the current insurance upon its properties and with respect to the conduct of its business;

(e) use best efforts to keep intact its present business organization and keep available the services of its present officers, employees and agents; and

(f) maintain accurately its books, records and accounts.

4.3 Interim Financial Statements Prior to Closing. ProMed Upland shall provide Group with the interim balance sheets and income statements of ProMed Upland for each of the monthly periods commencing on March 1, 2007 through the month preceding the Closing Date promptly upon completion but in no event later than five days before the Closing Date (the “Subsequent Monthly Interim Financial Statements”). The Subsequent Monthly Financial Statements shall fairly present in all material respects the financial condition and results of operation of ProMed Upland as of the date and for the periods set forth therein and shall be prepared in accordance with GAAP, applied on a consistent basis throughout the periods covered thereby, except that such Subsequent Monthly Interim Financial Statements may exclude footnotes, and as unaudited statements, are subject to normal recurring audit adjustments consistent with past practice. On the Closing Date there shall not have been any material adverse change to the financial condition of ProMed Upland as shown on the Subsequent Monthly Financial Statements, including no material adverse change in the assets and liabilities of ProMed Pomona as shown on the March Interim Financial Statements; provided, however that Group acknowledges that ProMed Upland may make the payment of the Stay Bonuses and the distribution to the ProMed Upland Shareholder described in the last paragraph of Section 4.1 subject to satisfaction of the cash Closing requirements set forth in Section 4.4.

4.4 Required Cash and Accounts Receivable at Closing. ProMed Upland shall have at Closing cash and accounts receivable in an amount not less than the total liabilities or obligations of ProMed Upland (whether absolute, accrued, contingent, or otherwise) incurred or accrued as of the Closing Date. The cash of ProMed Upland shall include cash sufficient to cover the sum of One Hundred Twenty-Two Thousand Two Hundred Seventy-Two ($122,272) in Physician Retention Bonuses which shall be deemed a liability of ProMed Upland. The accounts receivable included in the Subsequent Interim Financial Statement and the Closing Date Balance Sheet, are or will be, as the case may be, valid and existing and represent monies due for services performed in the ordinary course of business.

4.5 No Shop. Between the date of this Agreement and the Closing Date neither ProMed Upland, nor any of its affiliates, agents or representatives, shall directly or indirectly solicit, initiate, encourage, entertain or support any inquiry, proposal, or other offer from any other party relating to any transaction involving, directly or indirectly, the merger of ProMed Upland or the purchase of the assets or stock of ProMed Upland or any possible transaction or series of transactions as an alternative to the transactions contemplated hereby (“Competing Proposal”). To the extent ProMed Upland or the ProMed Upland Shareholder or any of ProMed Upland’s affiliates, agents or representatives receives any Competing Proposal, they shall promptly inform Group of such Competing Proposal and shall advise the potential purchaser that ProMed Upland is subject to this Agreement and therefore will not hold any discussions with such potential purchaser.

ProMed Upland and the ProMed Upland Shareholder recognize that (i) the covenants and the restrictions contained in this Section 4.5 are necessary, fundamental, and required for the protection of the transactions contemplated by this Agreement; (ii) such covenants relate to matters which are of a special, unique, and extraordinary character that gives such covenants a special, unique and extraordinary value; and (iii) a breach of the covenants contained in this Section 4.5 will result in irreparable harm and damage to Group which cannot be adequately compensated by a monetary award. In the event of such breach, and without limiting the right of Group to seek any other remedy or relief to which it may be entitled at law or in equity, each of ProMed Upland and the ProMed Upland Shareholder consent, without challenge or contest, to the immediate remedy of a temporary restraining order, preliminary injunction, or such other form of injunctive or equitable relief in favor of Group as may be used by any court of competent jurisdiction to restrain or enjoin ProMed Upland or the ProMed Upland Shareholder from breaching such covenant or to specifically enforce the provisions of this Section 4.5. ProMed Upland and the ProMed Upland Shareholder hereby waive any requirements that Group secure or post a bond in connection with obtaining injunctive relief or any other equitable relief.

4.6 Records of ProMed Upland. ProMed Upland agrees to deliver or cause to be delivered to Group the following as soon as possible after the execution of this Agreement but in no event later than ten (10) days after execution of this Agreement: (A) the eligibility tapes for each ProMed Upland Health Care Contract, (B) the physician credentialing records of all the physicians who are a party to the ProMed Upland Provider Contracts, (C) all patient records, including case management reports and notes, claims paid history (at least 24 months), and (D) any and all data relating to ProMed HCA’s management of ProMed Upland. Group shall maintain the confidentiality of the records delivered pursuant to this Section 4.6 to the same extent as it is required to apply to the Due Diligence Materials described in Section 5.4.

4.7 Enrollment Information and Eligibility Reports. ProMed Upland agrees to deliver to Group as soon as they have been prepared, all eligibility reports prepared after the date of execution of this Agreement through and including the Closing Date, and shall certify upon delivery that such reports are true, accurate and complete in all material respects, or shall describe any limitations to such certification.

4.8 No Change to Contracts with Chaparral Clinics; No Adverse Change by Chaparral Clinics to PCP and Specialist Agreements. ProMed Upland represents and agrees that it has not, nor has ProMed HCA on its behalf, amended or otherwise changed any term or condition (including capitation or fee for service rates) of any contracts between it and the Chaparral Clinics, including agreements for the provision of primary care or specialist physician services at the Chaparral Clinics, since January 1, 2007, and shall not so amend or change any terms or conditions through the Closing Date. As an affiliate of the Chaparral Clinics, ProMed Upland and the ProMed Upland Shareholder shall cause the Chaparral Clinics not to amend or change any of the Chaparral Clinic’s agreements with its primary care and specialist physicians where such amendment or change would adversely affect ProMed Upland (including rate increases affecting ProMed Upland) for a period of 24 months after the Closing Date, excepting only, in the case of specialist physicians, such annual increases to the specialist physicians that are approved by Group from time to time, in an amount not to exceed any rate increase received under the commercial HMO contracts.

4.9 ProMed LP. ProMed Upland is the owner of a 3.8% limited partnership interest in ProMed LP which owns the Ontario Building. ProMed Upland agrees that it shall sell all of its limited partnership interest in ProMed LP, and shall resign from any management or other positions with ProMed LP, prior to the Closing Date. On the Closing Date, (a) all indebtedness and other amounts (i) owed by ProMed Upland to ProMed LP or (ii) owed by ProMed LP to ProMed Upland shall be paid, cancelled, or eliminated (whether or not then due) and (b) any Liens relating to any of the aforesaid indebtedness or amounts shall be cancelled and shall be discharged of record. On the Closing Date, ProMed Upland shall not have any obligation, contractual or otherwise, to ProMed LP.

4.10 Closing Date Balance Sheet. Promptly upon completion, but no later than twenty five (25) days following the Closing Date, the ProMed Upland Shareholder and the ProMed Executive Officers shall deliver to Group the unaudited balance sheet of ProMed Upland for the period ending on the Closing Date prepared in accordance with GAAP.(the “Closing Date Balance Sheet”). As required by Section 4.4, ProMed Upland shall be obligated to have cash and/or accounts receivable in an amount to cover all of its liabilities or obligations as of the Closing Date, including the Physician Retention Bonus. ProMed Upland hereby covenants that all liabilities and obligations (whether absolute, accrued, contingent, or otherwise) incurred or accrued as of the Closing Date shall be set forth on the Closing Date Balance Sheet.

ARTICLE 5.

ADDITIONAL AGREEMENTS OF THE PARTIES

In order to induce Group and Holdings to enter into this Agreement and to consummate the Transaction, ProMed Upland and the ProMed Upland Shareholder, on the one hand, and Group and Holdings, on the other hand, enter into the agreements set forth in this Article 5.

5.1 Non-Competition of the Principal ProMed Executive Officers. As material inducement for the Transaction, each of the Principal ProMed Executive Officers are simultaneously herewith executing a non-competition agreement. Jeereddi Prasad, M.D. shall execute that non-competition agreement attached as Exhibit C (the “Prasad Non-Compete Agreement”), Kishan Thapar shall execute that non-competition agreement attached as Exhibit D (the “Thapar Non-Compete Agreement”), and Bahram Bahremand shall execute that non-competition agreement attached as Exhibit E (the “Bahremand Non-Compete Agreement”, and together with the Prasad Non-Compete Agreement and Thapar Non-Compete Agreement are collectively, the “Executive Officer Non-Compete Agreements”). The parties acknowledge that a portion of the Purchase Price is being allocated to the Executive Officer Non-Compete Agreements (“Covenant Allocation”). The Covenant Allocation shall not be deemed an estimate or measurement of damages incurred or suffered by Group or Holdings in the event of a breach of the Executive Officer Non-Compete Agreements.

5.2 Employees. The parties agree that Holdings or one of Holdings’ affiliates will offer an employment contract to each of the ProMed Executive Officers, namely: (i) Jeereddi Prasad, M.D., (ii) Kishan Thapar, M.D., and (iii) Bahram Bahremand, commencing at Closing pursuant to the terms and conditions of those employment agreements attached as Exhibit F (the “Prasad Employment Agreement”), Exhibit G (the “Thapar Employment Agreement”) and Exhibit H (the “Bahremand Employment Agreement”), respectively. The parties acknowledge

that as consideration for executing the Thapar Employment Agreement and Bahremand Employment Agreement, ProMed Pomona intends to pay stay bonuses in the amount of $63,568 to each of Kishan Thapar, M.D. and Bahram Bahremand prior to the Closing (“Stay Bonuses”)

5.3 Knowledge Standard. Whenever a representation, warranty, covenant or agreement is qualified by the statement “to the knowledge of”, the knowledge of ProMed Upland shall be deemed to be the actual knowledge of Jeereddi Prasad, M.D., President and Chairman of the Board of ProMed Upland, Kishan Thapar, M.D., Executive Director of ProMed Upland, and Bahram Barhemand, Chief Financial Officer of ProMed Upland, in each case after reasonable inquiry. Whenever a representation, warranty, covenant or agreement is qualified by the statement “to the knowledge of” any or all of Group, knowledge shall be deemed to be the actual knowledge of Jacob Y. Terner, M.D., Chief Executive Officer of Group, Mike Heather, Chief Financial Officer of Group, and R. Stewart Kahn, Secretary of Group, in each case after reasonable inquiry.

5.4 Due Diligence Access and Investigation. ProMed Upland shall, through the Closing Date, (a) afford Group and its representatives and attorneys (collectively, the “Prospect Advisors”) full and free access to ProMed Upland’s properties, contracts, books and records, and other documents and data during normal business hours, (b) furnish Group and the Prospect Advisors with copies of all such contracts, books and records, and other existing documents and data as Group may reasonably request, and (c) furnish Group and the Prospect Advisors with such additional financial, operating, and other data and information as Group may reasonably request, including such information necessary to allow Group to make a determination of the adequacy and sufficiency of the internal controls of ProMed Upland (collectively, “Due Diligence Materials”). ProMed Upland shall permit the Prospect Advisors to make copies of the Due Diligence Materials. Neither Group nor the Prospect Advisors shall disclose the contents of any of said Due Diligence Materials to any third party without prior written consent of the ProMed Upland Shareholder, except: (i) as required by law; (ii) as may be reasonably necessary in connection with any litigation or dispute arising out of this Agreement or any of the transactions contemplated hereunder; (iii) information contained in any such materials that was already in the possession of Group prior to the date of commencement of negotiations between the ProMed Parties and Group; (iv) information contained in any such materials that is or becomes generally available to the public other than as a result of a disclosure by Group or its agents or employees in violation of this Section and (v) as necessary in the reasonable operation of the business of ProMed Upland and the management obligations of the same after the Closing Date.

5.5 Tax Matters; Liability; Preparation and Filing of Tax Returns.

(a) Adequate Provision for Taxes. The Subsequent Monthly Interim Financial Statements shall reflect that ProMed Upland has made adequate provision for accrued but unpaid taxes for the period covered by such Subsequent Monthly Interim Financial Statements.

(b) Liability for Taxes. The ProMed Upland Shareholder will be liable for, and shall have properly accrued on the Subsequent Monthly Interim Financial Statements, all Taxes imposed on ProMed Upland, or for which ProMed Upland may otherwise be liable, for any Pre-Closing Tax Period (as defined below). The ProMed Upland Shareholder shall also be

liable for any Taxes arising as a result of any breach of the representation contained in Section 2.9 and the covenants contained in this Section 5.5, whether incurred before or after the Closing Date. “Pre-Closing Tax Period” means any period (including the portion of any Straddle Period as defined in (c) below) ending on or before the date before the Closing Date.

(c) Straddle Periods. Whenever it is necessary to determine the liability for Taxes of ProMed Upland for a period that begins before or after the day prior to the Closing Date (a “Straddle Period”), the determination of the Taxes of ProMed Upland for the portion of the Straddle Period ending on and including, and the portion of the Straddle Period beginning after, the day prior to the Closing Date will be determined by assuming that the Straddle Period consisted of two taxable years or periods, one which ended at the close of the day prior to the Closing Date and the other which began at the beginning of the day of the Closing Date, and, items of income, gain, deduction, loss or credit of ProMed Upland for the Straddle Period will be allocated between two taxable years or periods on a “closing of the books basis” by assuming that the books of ProMed Upland were closed at the close of the day prior to the Closing Date, provided, however, that exceptions, allowances or deductions that are calculated on an annual basis, such as the deduction for depreciation, will be apportioned between such two taxable years or periods on a daily basis.

(d) Tax Returns. Group will be responsible for causing the preparation and filing of all tax returns that are required to be filed by or with respect to ProMed Upland for the period commencing January 1, 2007 and ending on December 31, 2007 provided, however, that the ProMed Upland Shareholder shall be responsible for and liable for any taxes due for the Pre-Closing Period which has not been properly accrued on the Subsequent Monthly Interim Financial Statements for the period covered by such Subsequent Monthly Interim Financial Statements or properly accrued and shown on the records of ProMed Upland for the period ending on the Closing Date. No later than 30 days before the due date for filing any tax return described in this subsection (d) which is required to be prepared by Group after Closing involving any Pre-Closing Tax Period, Group will deliver such tax return to the ProMed Upland Shareholder for their review. Group and the ProMed Upland Shareholder will attempt to resolve in good faith any disagreement arising out of any tax return. If any such disagreement cannot be resolved, Group and the ProMed Upland Shareholder will jointly select an independent accounting firm to act as an arbitrator to resolve such disagreement in accordance with the terms of this Agreement. The independent accounting firm’s determination with respect to any such tax return will be final and binding upon the parties and all parties will file (or amend, if applicable) their respective tax returns in accordance with such determination. Any fees and expenses related to the engagement of the independent accounting firm will be shared equally by Group on the one hand and the ProMed Upland Shareholder on the other hand.

(e) 338 Election and 338 Taxes. Group intends to make an election under Section 338(h)(10) of the Internal Revenue Code of 1986, as amended (the “Code”) to treat the sale of the ProMed Upland Shares as a sale of assets by ProMed Upland for income and franchise tax purposes. Group and the ProMed Upland Shareholder shall duly and timely file, or cause to be duly and timely filed, any document necessary to effectuate such election including without limitation, federal Form 8023 (and any similar forms required under state or local laws relating to taxes) in accordance with the requirements of Section 338 of the Code (or state or local laws relating to the taxes, as the case may be). The parties shall report the deemed sale

consistent with such allocation for all financial, tax or other purposes, shall not take any position inconsistent therewith and shall cooperate with each other to take all actions necessary and appropriate as may be required to effect and preserve such election. Anything contained in this Agreement to the contrary notwithstanding, none of the ProMed Upland Shareholder makes any representation or warranty concerning the effectiveness under the Code (or other comparable provision of law) of any election made pursuant to this Section 5.5(e); and, except where such failure is due to a breach by such party of its obligations under this Section 5.5(e), in no event shall any of the ProMed Upland Shareholder be liable to Group for the failure of any such election to be effective under the Code (or other comparable provision of law).

(f) Contest Provisions. Promptly after receipt by Group or the ProMed Upland Shareholder of written notice of the assertion or commencement of any claim, audit, examination or other proposed change or adjustment by the Internal Revenue Service or any state, local or foreign taxing authority having jurisdiction over ProMed Upland or any of its assets (“Tax Authority”) relating to Taxes of ProMed Upland with respect to a Pre-Closing Tax Period (a “Tax Claim”), the recipient will promptly notify Group or the ProMed Upland Shareholder, as applicable. Such notice will contain factual information (to the extent known) describing the asserted Tax Claim in reasonable detail and will include copies of any notice or other document received from any Taxing Authority in respect of any such asserted Tax Claim. The failure of the ProMed Upland Shareholder to receive prompt notice from Group as provided in this Agreement will not relieve the ProMed Upland Shareholder of any of his indemnification obligations under this Agreement except to the extent such failure has a material adverse effect on the ProMed Upland Shareholder’ ability to defend the Tax Claim. The ProMed Upland Shareholder will have the right to represent ProMed Upland’s interests in any Tax audit or administrative or court proceeding relating to Pre-Closing Tax Periods as to any issues that could materially affect the ProMed Upland Shareholder’ liability for Taxes or indemnification obligations, and to employ counsel (reasonably acceptable to Group) of the ProMed Upland Shareholder’ choice at its expense; provided, however, that Group and their representatives will be permitted, at their expense, to be present at any such audit or proceeding. Notwithstanding the foregoing, the ProMed Upland Shareholder will not be able to settle, either administratively or after the commencement of litigation, any claim for Taxes that would adversely affect the liability for Taxes of Group or ProMed Upland for any period after the Closing Date without the written consent of Group unless the ProMed Upland Shareholder makes adequate provision to the satisfaction of Group to indemnify Group against the effects of any such settlement.

(g) Assistance and Cooperation. After the Closing Date, the ProMed Upland Shareholder and Group will:

(i) timely sign and deliver such certificates or forms as may be reasonably necessary or appropriate to establish an exemption from (or otherwise reduce), or file tax returns or other reports with respect to sales, transfer and similar Taxes;

(ii) assist as reasonably requested by the other party in preparing any tax return which such other party is responsible for preparing and filing in accordance with this Section 5.5 (including providing the other party with reasonable access to financial records for such purposes);

(iii) cooperate in a reasonable manner in preparing for any audits of, or disputes with taxing authorities regarding, any tax returns of ProMed Upland; and

(iv) make available to the other party and to any taxing authority as reasonably requested all information, records, and documents relating to Taxes of ProMed Upland.

5.6 Notification. Between the date of this Agreement and the Closing Date, the ProMed Parties on the one hand and Group and Holdings on the other hand agree to promptly notify each other in writing if they become aware of any fact or condition that causes or constitutes a breach of any of their representations and warranties as of the date of this Agreement, or if they become aware of the occurrence after the date of this Agreement of any fact or condition that would (except as expressly contemplated by this Agreement) cause or constitute a breach of any such representation or warranty had such representation or warranty been made as of the time of occurrence or discovery of such fact or condition. If prior to the Closing any event, condition, fact or circumstance that is required to be disclosed pursuant to this Section 5.6 requires any change to any of the Schedules to this Agreement, or if any such event, condition, fact or circumstance would require such a change assuming a Schedule was dated as of the date of the occurrence, existence or discovery of such event, condition, fact or circumstance, then ProMed Upland and the ProMed Upland Shareholder shall promptly deliver to Group an update to the Schedule (a “Schedule Update”) specifying such change. Group shall have 5 business days to review such Schedule Update and absent an objection by Group within such 5 day period, such Schedule Update shall be deemed to supplement or amend the Schedule for the purpose of determining the accuracy of any of the representations and warranties made by ProMed Upland or the ProMed Upland Shareholder in this Agreement as of the Closing.

5.7 Investment Representation Certificate. ProMed Upland acknowledges that the Holdings Common Stock which constitutes the Stock Consideration has not been registered under the Securities Act of 1933, as amended (the “Securities Act”). ProMed Upland acknowledges that the Holdings Common Stock is being offered and sold pursuant to an exemption from registration contained in the Securities Act. To rely on such exemption, ProMed Upland acknowledges that it is necessary that the ProMed Upland Shareholder executes an investment representation certificate in the form attached as Exhibit I (“Investment Representation Certificate”). The ProMed Upland Shareholders acknowledges that his execution of the Investment Representation Certificate is necessary for the issuance of the Stock Consideration and is also a requirement to receive the piggy-back registration rights described in Section 1.15 hereof

5.8 Attorney Fees of ProMed Upland. The legal fees of ProMed Upland with respect to the negotiation and drafting of the documentation in connection with the Upland Stock Purchase and the other transactions contemplated hereunder, which have not been accrued on the Subsequent Monthly Financial Statements but are still outstanding immediately after the Closing, shall be borne solely by the ProMed Upland Shareholder at no expense to ProMed Upland

5.9 Bank Accounts. ProMed Upland shall, prior to the Closing provide, City National Bank, which is the bank where the ProMed Bank Accounts are located (“ProMed Bank”) with all

documentation required to be provided by ProMed Upland to allow Group access to the funds in the ProMed Bank Accounts upon the Closing Date.

5.10 Amendment of Bylaws. Prior to Closing, ProMed Upland shall amend its Bylaws to allow acquisition of the shares by a California professional corporation whose sole shareholder is a licensed physician such as Group.

5.11 Right of First Refusal. Group shall have the right of first refusal (“Right of First Refusal”) in the event that the ProMed Upland Shareholder wishes to sell all or substantially all the stock, assets or business operations of the Chapparal Clinics (a “Covered Sale”). Group can assign its Right of First Refusal to any Affiliate (as defined in the Prasad Non-Compete Agreement). References to the rights of Group in this Section 5.11 shall be deemed to include references to each Affiliate of Group.

If at any time the ProMed Upland Shareholder desires to make a Covered Sale, then the ProMed Upland Shareholder shall, or shall cause the Chapparal Clinics, to do the following:

(a) Offer Notice. ProMed Upland Shareholder or Chapparal Clinics shall deliver a written notice of the proposed Covered Sale (the “Offer Notice”) to Group. The Offer Notice shall contain a description of the proposed Covered Sale and the terms of the proposed Covered Sale (the “Offer”), including (i) a description of the Covered Sale which is the subject of the proposal, (ii) a description of the type of proposed Covered Sale, including whether the Covered Sale will be made pursuant to a transfer of assets or equity interests and whether all or a portion of the assets are a part of the Covered Sale, (iii) the price at which the Covered Sale is proposed to be made to the proposed purchaser (the “Offered Price”), and (iv) the terms of payment of the Offered Price and the other material terms and conditions to the proposed Covered Sale to the proposed purchaser (the “Offered Terms and Conditions”).

(b) Acceptance. Group or any Affiliate of Group, shall have the right to purchase the assets and/or stock of the Chapparal Clinics described in the Offer Notice by written notice of acceptance (the “Acceptance Notice”) from Group to ProMed Upland Shareholder within 30 days of receipt of the Offer Notice. The failure by Group to deliver an Acceptance Notice within 30 days of receipt of the Offer Notice shall result in the waiver by Group of its right of first refusal as set forth herein and a termination of the right of first refusal.

(c) Due Diligence; Purchase and Sale Agreement. If Group accepts the Offer in accordance with this Agreement, it will have the later of (i) 30 days from the date of the ProMed Upland Shareholder’s receipt of Group’s timely Acceptance Notice or (ii) such other applicable timeframes specified in the Offer to (1) both commence (“Due Diligence Start Date”) and complete its due diligence of the Chapparal Clinics and (2) execute a Purchase and Sale Agreement providing for the Covered Sale on the terms of the Offer, with the Offer Terms and Conditions, and at the Offer Price, with customary representations, warranties, covenants and agreements as is typically set forth in a stock or asset sale, and with only such variations from the Offer as the ProMed Upland Shareholder and Group may reasonably agree (“Acceptable Purchase and Sale Agreement”). If as a result of the due diligence review, Group decides not to proceed with the Covered Sale, it shall deliver a written notice of rescission (“Rescission Notice”) to ProMed Upland Shareholder on or before the date that is 30 days after the later of (i)

the Due Diligence Start Date or (ii) such other applicable timeframes specified in the Offer (the date which is the later of (i) and (ii) being referred to as the “Due Diligence Deadline Date”). Additionally, regardless of whether or not Group delivers a Rescission Notice or whether or not Group has completed, or even commenced, its due diligence review, if Group, fails to execute an Acceptable Purchase and Sale Agreement within the later of (i) 45 days from the date of the ProMed Upland Shareholder’s receipt of Group’s timely Acceptance Notice or (ii) such other applicable timeframes specified in the Offer, then Group is deemed to have rescinded its Acceptance Notice and the right of first refusal shall be terminated.

(d) Closing. The closing of the Covered Sale pursuant to this Section 5.11 will take place at the time and place as set forth in the Offer, or upon such other time and place that ProMed Upland Shareholder and Group shall all agree upon; provided, that the date of closing shall be no later than the later of (A) 60 days of the delivery of the Acceptance Notice or (B) 10 days after the date all necessary third party consents have been obtained.

5.12 Good Faith. ProMed Upland and the ProMed Upland Shareholder on the one hand, and Group and Holdings on the other hand, agree that they will perform their obligations under this Agreement in good faith.

5.13 Physician Retention Bonus Pool. The parties acknowledge that the purpose of the Required Minimum Cash amount of $122,272 required by Section 4.4 is to fund a bonus pool (“Physician Retention Bonus”) to compensate physicians who agree to be exclusive to ProMed Upland, Group and Group’s affiliates in a form reasonably acceptable to Group. Upon reaching such agreement with Group, the physicians set forth on Schedule 5.13(a) shall be entitled to such portion of the Physician Retention Bonus as determined by Group. Group acknowledges that any physician who agrees to the exclusivity provisions set forth on Schedule 5.13(b) satisfies this requirement. Group agrees to use commercially reasonable efforts to obtain all amendments to the provider agreements evidencing exclusivity and pay out such Physician Retention Bonuses on or before September 30, 2007.

5.14 Best Efforts. So long as this Agreement remains in effect, ProMed Upland and the ProMed Upland Shareholder on the one hand, and Group and Holdings on the other hand, shall use their respective best efforts to cause the Transaction to be consummated as soon as reasonably practicable. ProMed Upland and the ProMed Upland Shareholder on the one hand, and Group and Holdings on the other hand, shall proceed as soon as practicable in the procurement of permits, consents and approvals and in the taking of any other action, and the satisfaction of all other requirements prescribed by law or otherwise necessary for consummation of the Transaction on the terms herein provided, and shall diligently prosecute the same.

5.15 Post-Closing IBNR Reconciliation. Group, as owner of ProMed Upland after the Closing Date, shall, for the period commencing on the Closing Date and ending eighteen (18) months thereafter, keep an account of claims received on or after the Closing Date for dates of service prior to the Closing Date and either paid from, or to be paid from, IBNR funds (“IBNR Claims”). On or prior to the date that is seven (7) business days after the second anniversary of the Closing Date (the “IBNR Reconciliation Date”), Group and the ProMed Upland Shareholder shall effect a reconciliation of the IBNR funds as set forth herein (“IBNR Reconciliation”). To effect the IBNR Reconciliation, the parties shall compare the amount of the IBNR reserve that

was set forth on the Closing Date Balance Sheet (“IBNR Closing Date Reserve Amount”) to the IBNR Claims. If the IBNR Claims were greater the amount of the IBNR Closing Date Reserve Amount plus an additional 10% above such IBNR Closing Date Reserve Amount (“Downward IBNR Reconciliation Threshold Amount”) then to the extent of the dollar amount by which the IBNR Claims exceeds the Downward IBNR Reconciliation Threshold Amount (“Shareholder IBNR Reimbursement Amount”), Group shall have the right to receive payment from the ProMed Upland Shareholder in the amount of the Shareholder IBNR Reimbursement Amount. On the other hand, if the IBNR Claims were less than the amount of the Closing Date Reserve Amount less an additional 10% below such IBNR Closing Date Reserve Amount (“Upward IBNR Reconciliation Threshold Amount”) (such difference constituting the “Group IBNR Reimbursement Amount), Group shall be required to immediately reimburse the ProMed Upland Shareholder the dollar amount of the Group Reimbursement Amount.

Example: Assume that the IBNR Closing Date Reserve Amount is $5,000,000 and thus the Downward Reconciliation Threshold Amount is $5,500,000 and the Upward Reconciliation Threshold Amount is $4,500,000. If the IBNR Claims are $5,600,000, then the ProMed Upland Shareholder IBNR Reimbursement Amount that would be owed by the ProMed Upland Shareholder would total $100,000 ($5,600,000 - $5,500,000). Conversely, if the IBNR Claims are $4,400,000, then the Group IBNR Reimbursement Amount owed by Group to the ProMed Upland Shareholder would be $100,000 ($4,500,000 - $4,400,000).

5.16 Post-Closing Balance Sheet Reconciliation: Closing Date Balance Sheet. Within three (3) business days of the delivery of the Closing Date Balance Sheet as provided by Section 4.10, Group and the ProMed Upland Shareholder shall effect a reconciliation of the cash and accounts receivable, on the one hand, and the liabilities and obligations of ProMed Upland, on the other hand (the “Closing Date Balance Sheet Reconciliation”). To effect the Closing Date Balance Sheet Reconciliation, the parties shall meet and compare the cash and accounts receivable shown on the Closing Date Balance Sheet Reserve Amount (“Balance Sheet Cash + A/R Amounts”) to the amount of cash and accounts receivable that was in existence in ProMed Upland on the Closing Date (in the case of the accounts receivable the parties will consider any accounts receivable that was determined since the date of the Closing to now be uncollectable and reflect that as a decrease in the total amount of cash and accounts receivable left in ProMed Upland) (“Closing Date Cash + A/R”) and will compare the liabilities and obligations showing on the Closing Date Balance Sheet (“Balance Sheet Liabilities”) to the liabilities and obligations shown on the Subsequent Monthly Interim Financial Statement for which the Closing Date Cash + A/R relates (“Originally Estimated Liabilities”). If the Balance Sheet Liabilities were greater than the amount of the Closing Date Cash + A/R, plus an additional 10% above such Closing Date Cash + A/R (the (“Downward Balance Sheet Reconciliation Threshold Amount”) then to the extent of the dollar amount by which the Balance Sheet Liabilities exceeds the Downward Balance Sheet Reconciliation Threshold Amount (“ProMed Upland Shareholder Balance Sheet Reimbursement Amount”), Group shall have the right to reimbursement of the amount of the ProMed Upland Shareholder Balance Sheet Reimbursement Amount from the ProMed Upland Shareholder. On the other hand, if the Balance Sheet Liabilities were less than the amount of the Closing Date Cash + A/R less an additional 10% below such Closing Date Cash + A/R (“Upward Balance Sheet Reconciliation Threshold Amount”) (such difference constituting the “Group Balance Sheet Reimbursement Amount), Group shall be required to immediately reimburse the ProMed Upland Shareholder the dollar amount of the Group Balance Sheet

Reimbursement Amount. The reconciliation hereunder shall exclude a reconciliation of IBNR which shall be handled in accordance with Section 5.15 hereof.

Example: Assume the Closing Date Cash + A/R is $5,000,000, thus the Downward Balance Sheet Reconciliation Threshold Amount is $5,500,000 and the Upward Reconciliation Threshold Amount is $4,500,000. If the Balance Sheet Liabilities are $5,600,000, then the ProMed Upland Shareholder Balance Sheet Reimbursement Amount that would be owed by the ProMed Upland Shareholder would total $100,000 ($5,600,000 - $5,500,000). Conversely, if the Balance Sheet Liabilities are $4,400,000, then the Group Balance Sheet Reimbursement Amount owed by Group would be $100,000 ($4,500,000 - $4,400,000).

Notwithstanding the foregoing, the reconciliation of liabilities and obligations in reliance on the Closing Date Balance Sheet shall not constitute a waiver by Group, the Surviving Corporation or their respective directors, officers, employees, agents and affiliates, or shall not otherwise limit the indemnification obligations of the ProMed Upland Shareholder under Article 7 hereof, for a breach of Sections 2.8, 4.4 and/or 4.10 to the extent any liabilities and obligations are not shown on the Closing Date Balance Sheet in accordance with the representations, covenants or agreements of those Sections as to matters as of the Closing Date or the Effective Time or the accounts receivable on the Closing Date Balance Sheet, or any portion thereof, is deemed not collectible.

5.17 Further Assurances. ProMed Upland and the ProMed Upland Shareholder on the one hand, and Group and Holdings on the other hand, agree that at any time and from time to time after the Closing Date they will execute and deliver to any other party such further instruments or documents as may reasonably be required to give effect to the Transaction.

ARTICLE 6.

DELIVERIES AND CONDITIONS

6.1 Deliveries by ProMed Upland and the ProMed Upland Shareholder on the Closing Date. On the Closing Date, ProMed Upland and the ProMed Upland Shareholder shall deliver to Group and Holdings:

(a) A copy of the Articles of Incorporation of ProMed Upland, with all amendments thereto, and certificate of good standing from the State of California, both of which shall be certified as of a date within ten days prior to the Closing Date by the Secretary of State of California.

(b) A certificate of tax good standing of ProMed Upland from the Franchise Tax Board issued as of a date within ten days of the Closing Date.

(c) A certificate executed by the President of ProMed Upland confirming (i) the truth and correctness in all material respects of all of ProMed Upland’s representations and warranties in this Agreement as of the Closing Date and as of all times between the date hereof and the Closing Date, and (ii) that all agreements and covenants of ProMed Upland specified herein to be complied with prior to the Closing Date have been complied with.

(d) A certificate of the Secretary of ProMed Upland dated the Closing Date and accompanying resolutions reflecting that the necessary corporate action by the Board of Directors of ProMed Upland and by the sole shareholder of ProMed Upland has been taken to authorize the consummation by ProMed Upland of the Transaction.

(e) A spousal consent of the ProMed Upland Shareholder for this Agreement.

(f) Letters of resignation of officers and directors of ProMed Upland as requested by Group.

(g) Original stock certificates representing the ProMed Upland Shares duly endorsed in blank for transfer and presented with stock powers duly endorsed in blank.

(h) The Prasad Employment Agreement, the Thapar Employment Agreement and the Bahremand Employment Agreement.

(i) The Prasad Non-Compete Agreement, the Thapar Non-Compete Agreement and the Barhemand Non-Compete Agreement.

(j) A legal opinion from counsel to ProMed Upland as to the matters set forth in Exhibit J.

6.2 Conditions to the Obligations of Group and Holdings. The obligation to pay the Purchase Price as set forth in this Agreement and to consummate the Transaction is conditioned upon satisfaction, or waiver by Group and Holdings in writing, of all of the following on or before the Closing Date:

(a) All of the representations and warranties of ProMed Upland and the ProMed Upland Shareholder in this Agreement must have been accurate in all material respects as of the date of this Agreement, and must be accurate in all material respects as of the Closing Date as if made on the Closing Date, except for such representations and warranties that address matters as of a specific date, which need only to have been true and accurate as of such date.

(b) All of the agreements, covenants and obligations that ProMed Upland and the ProMed Upland Shareholder are required to perform or to comply with pursuant to this Agreement at or prior to the Closing Date must have been duly performed and complied with in all material respects.

(c) Each document required to be delivered pursuant to Section 6.1 hereof must have been delivered to Group and Holdings.

(d) Since the date of this Agreement, there must not have been commenced or threatened against the ProMed Upland Shareholder, ProMed Upland, or any officer or director of ProMed Upland, any proceeding (i) involving any challenge to, or seeking damages or other relief in connection with part of the Transaction, or (ii) that may have the effect of preventing, delaying, making illegal, or otherwise interfering with any part of the Transaction.

(e) Group shall have satisfactorily (in the sole discretion of Group) completed its due diligence investigation of ProMed Upland.

(f) Group shall have obtained satisfactory (in the sole discretion of Group) financing for the cash portion of the Purchase Price.

(g) There shall have been no material adverse changes to the financial condition of ProMed Upland subsequent to its March Interim Financial Statement.

(h) The parties shall have obtained all necessary consents and approvals to the Transaction, including, without limitation, all Board of Directors and all shareholder consents and all necessary consents or approvals of third parties, including HMO consents.

(i) The parties shall have obtained all necessary approvals from applicable state and federal regulatory authorities.

(j) All conditions to the closings of the ProMed Pomona Acquisition and the ProMed Company Acquisition, respectively, have been satisfied and the consummation of each transaction is occurring simultaneously with the Closing herein.

6.3 Deliveries by Group and Holdings on the Closing Date. On the Closing Date, Group and Holdings shall deliver to the ProMed Parties.

(a) Certificates executed by the Chief Executive Officer of Group and Holdings confirming (i) the truth and correctness in all material respects of all of Group’s, Group Subsidiary’s and Holdings’ representations and warranties in this Agreement as of the Closing Date and as of all times between the date hereof and the Closing Date, and (ii) that all agreements and covenants of Group and Holdings specified herein to be complied with prior to the Closing Date have been complied with.

(b) Certificate of the secretaries of Group and Holdings dated the Closing Date, and accompanying resolutions reflecting that the necessary corporate action by the Board of Directors of Group and Holdings to authorize the consummation by Group and Holdings of the Transaction.

(d) The Prasad Non-Compete Agreement, the Thapar Non-Compete Agreement and the Barhemand Non-Compete Agreement.

(e) A legal opinion from counsel to Group as to the matters set forth in Exhibit M.

(f) The Purchase Price described in Section 1.3 hereof.

6.4 Conditions to the Obligations of ProMed Upland and the ProMed Upland Shareholder. The obligations of ProMed Upland and the ProMed Upland Shareholder to

consummate the Transaction is conditioned upon satisfaction, or waiver by ProMed Upland and the ProMed Upland Shareholder in writing, of all of the following on or before the Closing Date:

(a) All of the representations and warranties of Group and Holdings in this Agreement must have been accurate in all material respects as of the date of this Agreement, and must be accurate in all material respects as of the Closing Date as if made on the Closing Date, except for such representations and warranties that address matters as of a specific date, which need only to have been true and accurate as of such date.

(b) All of the agreements, covenants and obligations that Group and Holdings are required to perform or to comply with pursuant to this Agreement at or prior to the Closing Date must have been duly performed and complied with in all material respects.

(c) Each document required to be delivered pursuant to Section 6.3 hereof must have been delivered to ProMed Upland and the ProMed Upland Shareholder.

(d) Since the date of this Agreement, there must not have been commenced or threatened against Group, Holdings or any officer or director of Group or Holdings, any Proceeding (i) involving any challenge to, or seeking damages or other relief in connection with, any part of the Transaction, or (ii) that may have the effect of preventing, delaying, making illegal, or otherwise interfering with any part of the Transaction. Any third party approvals or consents required to be obtained to effectuate the Transaction shall have been received.

ARTICLE 7.

INDEMNIFICATION; REMEDIES

7.1 Indemnification Period. As used in this Article 7, the “Indemnification Period” shall be that period of time commencing on the Closing Date and continuing for two (2) years thereafter.

7.2 Indemnification of Group and Holdings. The ProMed Upland Shareholder shall indemnify, defend and hold harmless Group and Holdings and their directors, officers, employees, agents and affiliates from and against any and all damage, loss, liability and expense (including without limitation (A) reasonable expenses of investigation and reasonable attorneys’ fees and reasonable expenses in connection with any action, suit or proceeding, (B) any fees and expenses in connection with the retention of counsel to pursue insurance coverage, (C) any amounts paid to defend, litigate, settle, satisfy a judgment, or otherwise resolve disputes with the insurance carrier, if any, or the claimant, and (D) all amounts not covered by insurance incurred or suffered by Group or Holdings arising out of (i) any breach of the representations, warranties, covenants or agreements of ProMed Upland and/or the ProMed Upland Shareholder set forth herein, (ii) any failure by ProMed Upland or the ProMed Upland Shareholder to perform or comply with any covenant contained in this Agreement that is required to be performed or complied with by ProMed Upland or the ProMed Upland Shareholder as set forth herein, and/or (iii) any action against Group, Group Subsidiary, Holdings or any of their affiliates arising from or based upon an allegation of intentional tortious conduct any officer, employee or agent of ProMed Upland (including, but not limited to, any claims of wrongful termination, sexual harassment, racial or sexual discrimination) that occurred prior to the Closing Date (collectively,

the “Prospect Indemnifiable Damages”). Notwithstanding the foregoing, and except as otherwise specifically provided in Section 7.4, the ProMed Upland Shareholder shall not be obligated to indemnify Group or Holdings for any Prospect Indemnifiable Damages that exceed Five Hundred Thousand Dollars ($500,000) (the “Indemnification Cap”). Group, Group and/or Holdings may obtain indemnification for any Prospect Indemnifiable Damages to which this Section 7.2 relates only if it makes a claim for indemnification within the Indemnification Period defined in Section 7.1, except as otherwise provided in Section 7.4

7.3 Indemnification of the ProMed Upland Shareholder. Group and Holdings, jointly and severally, agree to hold harmless, defend and indemnify the ProMed Upland Shareholder from and against any and all damage, loss, liability and expense (including without limitation (A) reasonable expenses of investigation and reasonable attorneys’ fees and reasonable expenses in connection with any action, suit or proceeding, (B) any fees and expenses in connection with the retention of counsel to pursue insurance coverage, (C) any amounts paid to defend, litigate, settle, satisfy a judgment, or otherwise resolve disputes with the insurance carrier, if any, or the claimant; and (D) all amounts not covered by insurance) incurred or suffered by the Seller or ProMed Upland Shareholder arising out of (i) any breach of the representations, warranties, covenants or agreements of Group or Holdings set forth herein (ii) any failure by Group or Holdings to perform or comply with any covenant contained in this Agreement that is required to be performed or complied with by Group or Holdings as set forth herein (the “Seller Indemnifiable Damages”). Notwithstanding the foregoing, neither Group nor Holdings shall be obligated to indemnify the ProMed Upland Shareholder for Seller Indemnifiable Damages in excess of the Indemnification Cap. The ProMed Upland Shareholder may obtain indemnification for any ProMed Indemnificable Damages to which this Section 7.3 relates only if it makes a claim for indemnification within the Indemnification Period defined in Section 7.1.

7.4 Exclusion of Prospect Indemnifiable Damages from Indemnification Period and Indemnification Cap. Notwithstanding anything in this Agreement to the contrary, neither the Indemnification Period nor the Indemnification Cap shall apply to limit Prospect Indemnifiable Damages with respect to claims of Group or Holdings described in (i) through (iii) below, which in each case (A) shall be limited as to period by the statute of limitations period applicable to claims of that particular nature and (B) shall be limited as to amount of the Purchase Price.

(i) under Section 7.2(iii);

(ii) arising out of or related to a breach of any or all of the representations, warranties, covenants or agreements set forth in Section 2. 10; and/or

(iii) fraud.

7.5 Indemnification Procedures. A party seeking indemnification (the “Indemnitee”) shall use its best efforts to minimize any liabilities, damages, deficiencies, claims, judgments, assessments, costs and expenses in respect of which indemnity may be sought under this Agreement. The Indemnitee shall give prompt written notice to the party from whom indemnification is sought (the “Indemnitor”) of the assertion of a claim for indemnification, but in no event longer than twenty (20) days after service of process in the event litigation is commenced against the Indemnitee by a third party. No such notice of assertion of a claim shall

satisfy the requirements of this Section 7.5 unless it describes in reasonable detail and in good faith the facts and circumstances, to the extent known by Indemnitee, upon which the asserted claim for indemnification is based. If any action or proceeding shall be brought in connection with any liability or claim to be indemnified hereunder, the Indemnitee shall provide the Indemnitor twenty (20) calendar days to decide whether to defend such liability or claim. During such period, the Indemnitee shall take all necessary steps to protect the interests of itself and the Indemnitor, including the filing of any necessary responsive pleadings, the seeking of provisional relief or other action necessary to maintain the status quo, subject to reimbursement from the Indemnitor of its expenses in doing so. The Indemnitor shall (with, if necessary, reservation of rights) defend such action or proceeding at its expense, using counsel selected by the insurance company insuring against any such claim and undertaking to defend such claim, or by other counsel selected by it and approved by the Indemnitee, which approval shall not be unreasonably withheld or delayed. The Indemnitor shall keep the Indemnitee fully apprised at all times of the status of the defense and shall consult with the Indemnitee prior to the settlement of any indemnified matter. The Indemnitee agrees to use reasonable efforts to cooperate with the Indemnitor in connection with its defense of indemnifiable claims. In the event the Indemnitee has a claim or claims against any third party arising out of or connected with the indemnified matter, then upon receipt of indemnification, the Indemnitee shall fully assign to the Indemnitor the entire claim or claims to the extent of the indemnification actually paid by the Indemnitor and the Indemnitor shall thereupon be subrogated with respect to such claim or claims of the Indemnitee.

7.6 No Effect on ProMed Company Acquisition and/or ProMed Pomona Acquisition. The indemnification limitations contained in this Article 7 do not serve to limit the indemnification obligations of the ProMed Upland Shareholder in the ProMed Company and/or ProMed Pomona Acquisitions. Therefore, the ProMed Upland Shareholder, as a principal ProMed shareholder and an executive officer in the ProMed Company and/or ProMed Pomona transactions and thus subject to an indemnification obligation in those transactions, shall be obligated to indemnify Group, Holdings, Holdings’ affiliate, ProMed Company or ProMed Pomona to the extent provided in such acquisition documents.

7.7 Determination of Adverse Consequences. Any calculation of Prospect Indemnifiable Damages in respect of the indemnification obligations of the ProMed Upland Shareholder and the under this Article 7 shall be net of the amount of any insurance recovery actually received by any of Group or ProMed Upland. Group shall use commercially reasonable efforts to secure any applicable insurance recoveries to the extent applicable.

ARTICLE 8.

TERMINATION

8.1 Termination Events. The Agreement may, by notice given prior to or at the Closing, be terminated as follows:

(a) Upon the mutual written consent of Group on the one hand and the ProMed Parties on the other hand, this Agreement may be terminated on such terms and conditions as agreed; or

(b) By written notice of Group on the one hand and the ProMed Parties on the other hand if ProMed Upland or the ProMed Upland Shareholder breaches in any material respect any of its representations or warranties or defaults in any material respect in the observance or in the due and timely performance of any of its covenants or agreements herein contained and such breach or default shall not be cured prior to the earlier of the Closing Date or 30 days of the date of notice of breach or default served by Group; or

(c) By written notice of the ProMed Parties on the one hand and to Group on the other hand if Group breaches in any material respect any of its representations or warranties or defaults in any material respect in the observance or in the due and timely performance of any of its covenants or agreements herein contained and such breach or default shall not be cured prior to the earlier of the Closing Date or 30 days of the date of notice of breach or default served by the ProMed Parties; or

(d) By written notice of Group to the ProMed Parties or by the ProMed Parties to Group if any court of competent jurisdiction shall have issued any order, decree or ruling or taken any other action restraining, enjoining or otherwise prohibiting the contemplated transactions; or

(e) By written notice of Group to the ProMed Parties, or by the ProMed Parties to Group, if any court, legislative body or governmental or regulatory authority has taken, or is reasonably expected to take, any action that would make the consummation of the transactions contemplated hereby inadvisable or undesirable as determined by Group or the ProMed Parties in its sole discretion; or

(f) By written notice of Group to the ProMed Parties if it shall become apparent in the judgment of Group reasonably exercised that any condition to Group’s obligation to close as set forth in Article 6 hereof will not be satisfied before the Closing Date; or

(g) By written notice of the ProMed Parties to Group if it shall become apparent in the judgment of the ProMed Parties reasonably exercised that any condition to the ProMed Parties’ obligation to close as set forth in Article 6 hereof will not be satisfied before the Closing Date.

Notwithstanding the foregoing, no party hereto may effect a termination hereof at such time such party is in material default or breach of this Agreement.

8.2 Effect of Termination. Each party’s right of termination under Section 8.1 is in addition to any other rights it may have under this Agreement or otherwise, and the exercise of a right to termination will not be an election of remedies. If this Agreement is terminated pursuant to Section 8.1, all further obligations of the parties under this Agreement will terminate, provided, however, that if this Agreement is terminated by a party because of the breach of the Agreement by the other party or because one or more of the conditions to the terminating party’s obligations under this Agreement is not satisfied as a result of the other party’s failure to comply with its obligations under this Agreement, the terminating party’s right to pursue all legal remedies will survive such termination unimpaired.

8.3 Liquidated Damages.

(a) Notwithstanding anything to the contrary in this Agreement, if this Agreement is terminated for any reason other than pursuant to Section 8.1(a), Section 8.1(c), Section 8.1(d), Section 8.1(e) or Section 8.1(g) hereof, the parties agree and acknowledge that Group will suffer damages that are not practicable to ascertain. Accordingly, in the event this Agreement is terminated for any reason other than Section 8.1(a), 8.1(c), Section 8.1(d) , Section 8.1(e) or Section 8.1(g) hereof, Group shall be entitled to the sum of Two Hundred Fifty Thousand Dollars ($250,000) payable by ProMed Upland as liquidated damages. Group and ProMed Upland agree that the foregoing liquidated damages are reasonable considering all the circumstances existing as of the date hereof and constitute the parties good faith estimate of the actual damages reasonably expected to result from the termination of this Agreement other than under Section 8.1(a), Section 8.1(c), Section 8.1(d), Section 8.1(e) or Section 8.1(g). Notwithstanding the foregoing, the parties agree that if Group receives the $250,000 liquidated damages amount from ProMed Upland as a result of a termination under this Article 8, Group shall not be able to collect any additional liquidated damages fee under its agreement with ProMed Pomona, and Holdings shall not be able to collect any additional liquidated damages under its agreement with ProMed Company and ProMed Pomona, as a result of a termination of those agreements, to the extent Group or Holdings’ receipt of such liquidated damages would exceed $250,000 in the aggregate for the termination of the agreements with ProMed Pomona and ProMed Company.

(b) Notwithstanding anything to the contrary in this Agreement, if this Agreement is terminated for any reason other than pursuant to Section 8.1(a), Section 8.1(b), Section 8.1(d), Section 8.1(e) or Section 8.1(f) hereof, the parties agree and acknowledge that ProMed Upland will suffer damages that are not practicable to ascertain. Accordingly, in the event this Agreement is terminated for any reason other than Section 8.1(a), Section 8.1(b), Section 8.1(d), Section 8.1(e) or Section 8.1(f) hereof, ProMed Upland shall be entitled to the sum of Two Hundred Fifty Thousand Dollars ($250,000) payable by Group as liquidated damages. Group and ProMed Upland agree that the foregoing liquidated damages are reasonable considering all the circumstances existing as of the date hereof and constitute the parties good faith estimate of the actual damages reasonably expected to result from the termination of this Agreement other than under Section 8.1(a), Section 8.1(b), Section 8.1(d), Section 8.1(e) or Section 8.1(f). Notwithstanding the foregoing, the parties agree that if ProMed Upland receives the $250,000 liquidated damages amount from Group as a result of a termination under this Article 8, neither ProMed Pomona nor ProMed Company shall not be able to collect any additional liquidated damages fee under the agreements for the ProMed Company Acquisition and the ProMed Pomona Acquisition as a result of a termination of those agreements, to the extent the ProMed Pomona or ProMed Company’s receipt of such liquidated damages would exceed $250,000 in the aggregate for the termination of the agreements with ProMed Pomona, ProMed Upland and ProMed Company.

ARTICLE 9.

MISCELLANEOUS

9.1 Entire Agreement. This Agreement, together with all exhibits and schedules hereto, and all documents referred to herein, constitutes the entire agreement between the parties with respect to the subject matter hereof, supersedes all other and prior agreements on the same subject, whether written or oral, and contains all of the covenants and agreements between the

parties with respect to the subject matter hereof. Each party to this Agreement acknowledges that no representations, inducements, promises, or agreements orally or otherwise, have been made by the party(ies), or by anyone acting on behalf of any party, that are not identified herein, and that no other agreement, statement, or promise not contained in this Agreement shall be valid or binding. Certain matters that are listed in the Schedules to this Agreement are for informational purposes only and in no event shall the listing of any matters in these Schedules be deemed to constitute an admission that such matters are required to be listed therein by the terms of this Agreement or that such matters are otherwise material. In no event shall the listing of any matters in these Schedules be deemed or interpreted to broaden or otherwise amplify any representations or warranties contained in the Agreement.

9.2 Arbitration. In the event of a dispute under this Agreement which is not resolved after good faith negotiation, either Group or Group Subsidiary on the one hand or the ProMed Parties on the other hand may demand arbitration of the matter and the matter shall be settled by arbitration conducted by a single neutral arbitrator. Any such arbitration shall be held in Los Angeles County, California under the rules then in effect of the American Arbitration Association. The decision shall be written and shall be supported by, as agreed by the parties, either a reasoned award or findings of fact and conclusions which shall set forth the award, judgment, decree or order awarded by the arbitrator. The prevailing party to an arbitration shall be entitled to recovery from the non-prevailing party of the fees of the arbitrator, the administrative costs of the arbitration, and the expenses, including, without limitation, reasonable attorneys’ fees and costs, reasonably incurred by it in connection with the arbitration. Judgment upon any award rendered by the arbitrator may be entered in any court having jurisdiction. Notwithstanding the foregoing, the parties shall have the rights to discovery in accordance with California Code of Civil Procedure Section 1283.05.

9.3 Successors and Assigns. This Agreement and all documents and agreements referred to herein shall be binding upon and shall inure to the benefit of the parties and their respective heirs (as applicable), legal representatives, and permitted successors and assigns. No party may assign this Agreement or the rights, interests or obligations hereunder except by mutual written consent of the parties thereto.

9.4 No Waiver. No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be or be construed as a further or continuing waiver of any such term, provision or condition or as a waiver of any other term, provision or condition of this Agreement.

9.5 Counterparts. This Agreement, and any amendments hereto, may be executed in counterparts, each of which shall constitute an original document, but which together shall constitute one and the same instrument.

9.6 Headings. The section headings contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement.

9.7 Notices. Any notices required or permitted to be given hereunder by any party to the other shall be in writing and shall be deemed delivered upon personal delivery; twenty-four

(24) hours following deposit with a courier for overnight delivery; or five (5) business days following deposit in the U.S. Mail, registered or certified mail, postage prepaid, return- receipt requested, addressed to the parties at the following addresses or to such other addresses as the parties may specify in writing:

If to ProMed Upland:		Upland Medical Group, A Professional Medical Corporation. 4150 E. Concours St., Suite 100 Ontario, CA 91764 Attn: Jeereddi Prasad, M.D.

If to ProMed Upland Shareholder:

In each case, with a copy to:		Stradling Yocca Carlson & Rauth 660 Newport Center Drive, 16th floor Newport Beach, CA 92660 Attn: Shivbir S. Grewal, Esq.

If to Group:		Prospect Medical Group, Inc. 1920 East 17th Street Suite 200 Santa Ana, California 92705 Attn: Jacob Y. Terner, M.D.

If to Holdings:		Prospect Medical Group, Inc. 400 Corporate Pointe, Suite 525 Culver City, CA 90230 Attn: Jacob Y. Terner, M.D.

In each case, with a copy to:		Theodora Oringher Miller & Richman 2029 Century Park East, 6th Floor Los Angeles, CA 90067 Attn: Dale S. Miller, Esq.

9.8 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California.

9.9 Amendment. This Agreement may be amended at any time by agreement of the parties, provided that any amendment shall be in writing and executed by all parties.

9.10 Severability. If any provision of this Agreement is held by a court of competent jurisdiction to be invalid or unenforceable, the remaining provisions will nevertheless continue in full force and effect, unless such invalidity or unenforceability would defeat an essential business purpose of this Agreement.

9.11 Fees and Expenses. Except as otherwise explicitly set forth herein, each party shall bear its own expenses including, without limitation, attorneys’ and accountants’ fees in connection with the preparation of this Agreement and the transactions contemplated hereby.

9.12 Exhibits and Schedules. All exhibits and schedules attached to this Agreement are incorporated herein by this reference and all references herein to “Agreement” shall mean this Agreement together with all such exhibits and schedules to be delivered at the execution of this Agreement or upon the Closing Date.

9.13 Time of Essence. Time is expressly made of the essence of this Agreement and each and every provision hereof of which time of performance is a factor.

9.14 Attorneys’ Fees. Should any party institute any action or procedure to enforce this Agreement or any provision hereof, or for damages by a declaration of rights hereunder including without limitation arbitration, the prevailing party in any such action or proceeding shall be entitled to receive from the other party all costs and expenses, including without limitation reasonable attorneys’ fees, incurred by the prevailing party in connection with such action or proceeding.

9.15 Further Assurances. The parties shall take such actions and execute and deliver such further documentation as may reasonably be required in order to give effect to the transaction contemplated by this Agreement and the intentions of the parties hereto.

9.16 References to Dollars. All references to “dollars” and “$” shall mean United States dollars.

9.17 Construction. Whenever in this Agreement the context so requires, references to the masculine shall be deemed to include the feminine and the neuter, reference to the neuter shall be deemed to include the masculine and feminine, references to the plural shall be deemed to include the singular and the singular to include the plural and references to the words “and” and “or” shall be deemed to include the inclusive usage “and/or.”

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.

	“Group”

	PROSPECT MEDICAL GROUP, INC.


	By:
		Jacob Y. Terner, M.D.
		Chief Executive Officer


	“Holdings”

	PROSPECT MEDICAL HOLDINGS, INC.


	By:
		Jacob Y. Terner, M.D.
		Chief Executive Officer


	“ProMed Upland”

	UPLAND MEDICAL GROUP, A PROFESSIONAL
	MEDICAL CORPORATION


	By:
		Jeereddi Prasad, M.D.
		President


	“ProMed Upland Shareholder”


	Jeereddi Prasad, M.D.